

1 Sulfur Amino Acid Restriction Enhances Exercise Capacity in Mice 2 by Boosting Fat Oxidation in Muscle

3 Charlotte G Mann¹, Michael R MacArthur^{2,3,4}, Jing Zhang¹, Songlin Gong¹, Jenna E
4 AbuSalim^{3,4,5}, Craig J. Hunter^{2,3,4}, Wenyun Lu^{2,3}, Thomas Agius⁶, Alban Longchamp^{6,7,8},
5 Florent Allagnat⁶, Joshua Rabinowitz^{2,3,4,5}, James R Mitchell^{1,9}, Katrien De Bock¹, and Sarah
6 J Mitchell^{4*}

7 ¹Department of Health Sciences and Technology, ETH Zurich, Zurich 8092, Switzerland

8 ²Department of Chemistry, Princeton University, Princeton, NJ 08544, USA

9 ³Lewis-Sigler Institute of Integrative Genomics, Princeton University, Princeton, NJ 08544, USA

10 ⁴Ludwig Institute for Cancer Research, Princeton University, Princeton, NJ 08544, USA

11 ⁵Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA

12 ⁶Department of Vascular Surgery, Lausanne University Hospital (CHUV), Lausanne 1005, Switzerland.

13 ⁷Transplant Center, Department of Surgery, Massachusetts General Hospital, Harvard Medical School,
14 Boston, MA 02114, USA.

15 ⁸Center for Engineering in Medicine, Department of Surgery, Massachusetts General Hospital, Harvard
16 Medical School, Boston, MA 02114, USA.

17 ⁹Department of Molecular Metabolism, Harvard T.H. Chan School of Public Health, Boston, MA 02115,
18 USA

19

20 ***Corresponding author:**

21 Sarah J Mitchell, sm3272@princeton.edu

22

23

24 **Summary**

25 Dietary restriction of the sulfur-containing amino acids methionine and cysteine (SAAR)
26 improves body composition, enhances insulin sensitivity, and extends lifespan; benefits
27 seen also with endurance exercise. Yet, the impact of SAAR on skeletal muscle remains
28 largely unexplored. Here we demonstrate that one week of SAAR in sedentary, young, male
29 mice increases endurance exercise capacity. Indirect calorimetry showed that SAAR
30 increased lipid oxidation at rest and delayed the onset of carbohydrate utilization during
31 exercise. Transcriptomic analysis revealed increased expression of genes involved in fatty
32 acid catabolism especially in glycolytic muscle following SAAR. These findings were
33 functionally supported by increased fatty acid circulatory turnover flux and muscle β -oxidation.
34 Reducing lipid uptake from circulation through endothelial cell (EC)-specific CD36 deletion
35 attenuated the running phenotype. Mechanistically, VEGF-signaling inhibition prevented
36 exercise increases following SAAR, without affecting angiogenesis, implicating noncanonical
37 VEGF signaling and EC CD36-dependent fatty acid transport in regulating exercise capacity
38 by influencing muscle substrate availability.

39 Introduction

40 Caloric restriction (CR) is the gold standard to increase life and health span in various model
41 organisms (Fontana and Partridge, 2015). The reduction of calories was first shown to
42 increase lifespan in mammals early in the 20th century (McCay et al., 1935; Osborne et al.,
43 1917). Ever since, different modalities and degrees of restriction have been introduced and
44 studied in their efficacy in extending health- and lifespan (Lee et al., 2021). Dietary restriction
45 of the sulfur-containing amino acids methionine and cysteine (SAAR) improves body
46 composition, reverses insulin resistance and extends lifespan in rodents (Miller et al., 2005;
47 Orentreich et al., 1993) by eliciting strong metabolic effects. In brown adipose tissue (BAT),
48 SAAR increases thermogenesis and energy expenditure (EE), while also increasing lipolysis
49 and oxidative phosphorylation in white adipose tissue (WAT) and the liver (Forney et al., 2020;
50 Hasek et al., 2010; Patil et al., 2015). The effects of SAAR in skeletal muscle have been less
51 well studied.

52 Due to its large overall mass and high metabolic activity, skeletal muscle plays crucial roles in
53 the maintenance of systemic homeostasis. Skeletal muscles differ in fiber type composition,
54 traditionally categorized by their myosin heavy-chain content, but also in their metabolic
55 profiles and energy substrate preferences (Egan and Zierath, 2013; Rowe et al., 2014). The
56 extensor digitorum longus (EDL) and the soleus, are characterized as fast and slow twitch
57 muscles respectively, as they use glycolysis versus oxidative phosphorylation as the dominant
58 energy source (Brooke and Kaiser, 1970; Brown, 1973). Muscle fibers adapt to endurance
59 exercise training, enabling better responses to future challenges. These adaptations include
60 the promotion of fiber type transformation (from type IIb/IIc/x to IIa), mitochondrial biogenesis,
61 enhanced insulin sensitivity and improved metabolic flexibility. It has been reported that
62 muscle vascularization correlates with mitochondrial density and oxidative capacity (Haas and
63 Nwadozi, 2015) and endurance exercise stimulates angiogenesis in skeletal muscle.
64 Interestingly, the increase in insulin sensitivity, muscle angiogenesis and improved metabolic
65 flexibility are also observed after SAAR, but whether and how SAAR affects skeletal muscle
66 metabolic homeostasis is not known.

67 Previous research has shown that SAAR increases angiogenesis in skeletal muscle
68 (Longchamp et al., 2018). Angiogenesis is a crucial adaptive response in both developmental
69 and pathophysiological conditions characterized by insufficient oxygen and nutrient supply
70 (Potente et al., 2011). Endurance exercise is one of the few non-pathological settings of
71 vascular expansion during adulthood. During angiogenesis transcription factors like PGC1 α/β ,
72 estrogen-related receptor (ERR) α/γ , and activating transcription factor 4 (ATF4), are induced
73 by various stimuli including mechano-stress responses or the integrated stress response
74 (ISR). The ISR can be triggered by either endoplasmic reticulum (ER) stress or amino acid
75 (AA) deprivation (Abcouwer et al., 2002; Fan et al., 2021). These adaptive responses play
76 pivotal roles in regulating muscle metabolism and vascular density by enhancing vascular
77 endothelial growth factor (VEGF) levels (Arany et al., 2008; Gorski and Bock, 2019; Matsakas
78 et al., 2012; Narkar et al., 2011; Rowe et al., 2011). VEGF-A is the primary regulator of
79 angiogenesis. By binding to the receptor VEGFR2 VEGF-A initiates a cascade of signal-
80 transduction involving pathways including phosphoinositide 3-kinase (PI3K) and mitogen-
81 activated protein kinase (MAPK), facilitating EC migration, proliferation, and vessel formation
82 (Olsson et al., 2006). VEGF signaling also induces changes in energy metabolism, promoting
83 increased glucose uptake and glycolysis in ECs to meet the energy demands of migration (De

84 Bock et al., 2013). The role of the other VEGF isoforms is less understood. Initially considered
85 to passively regulate angiogenesis by scavenging VEGFR1 (Robciuc et al., 2016), research
86 suggests that VEGF-B may actively modulate EC fatty acid uptake (Dijkstra et al., 2014;
87 Falkevall et al., 2017; Hagberg et al., 2010; Kivelä et al., 2019; Mehlem et al., 2016; Ning et
88 al., 2020).

89 CR as well as SAAR have been shown to promote revascularization and recovery from
90 femoral artery ligation in rodents (Kondo et al., 2009; Longchamp et al., 2018) and the ability
91 to maintain vascular health in rodents and non-human primates in part by preserving capillary
92 density in skeletal muscle via regulation of VEGF (Omodei and Fontana, 2011). It is unknown
93 whether the SAAR dependent increase in capillary density in skeletal muscle induces
94 functional changes and if this is sufficient to increase exercise performance. Further, the role
95 of VEGF in this process is unexplored.

96 Here we show that short-term SAAR is sufficient to induce the metabolic benefits of SAAR
97 while also increasing endurance exercise capacity in young, sedentary, male mice. This is
98 achieved by mimicking the metabolic effects of endurance exercise in glycolytic muscle, which
99 requires active lipid transport and occurs through noncanonical VEGF signaling.

100 **Results**

101 **Short-term SAAR induces shifts in metabolism and increases endurance** 102 **exercise capacity in young, sedentary, male mice**


103 To evaluate the effect of short-term SAAR on systemic metabolism, we performed SAAR for
104 seven days in young, sedentary, male mice. Metabolic parameters included indirect
105 calorimetry and daily measurement of food intake and body weight. Exercise parameters
106 included a one-time maximal endurance treadmill test on day seven (experimental scheme,
107 Figure 1A). Seven days of SAAR reduced body weight by an average of 8.65% (Figures 1B
108 and S1A) and increased food intake (Figure 1C), consistent with previous reports on SAAR
109 (Miller et al., 2005; Orentreich et al., 1993). Lean to fat mass ratio was not changed by SAAR
110 (Figures S1B-D).

111 To further understand systemic metabolic changes following seven days of SAAR, we
112 performed indirect calorimetry using metabolic cages, including voluntary running wheels.
113 After seven days, mice on SAAR showed elevated EE during both the active and passive
114 phase (Figures S1E-F). Additionally, seven days of SAAR lowered the respiratory exchange
115 ratio (RER) (Figures 1D-E) without any alterations in voluntary wheel running or overall
116 locomotion (Figures 1F and S1G-H).

117 To test whether the effects on systemic metabolism translate to functional changes, we
118 measured maximal endurance exercise capacity using a one-time treadmill test to exhaustion.
119 Seven days of dietary SAAR significantly increased endurance exercise capacity in sedentary,
120 young, male mice (Figure 1G), where SAAR mice ran approximately 1.5 times longer than
121 control animals (956.5 ± 306.7 m and 634.8 ± 347.3 m respectively). Running performance
122 was independent of both absolute body weight at testing and relative changes in body weight
123 during studies (Figures S1I-J).

124 SAAR is reported to have several sexually dimorphic phenotypes (Jonsson et al., 2021;
 125 Wanders et al., 2017; Yu et al., 2018), therefore we checked whether the running endurance
 126 phenotype showed sexual specificity. Although young female mice did have lower body weight
 127 after SAAR (Figure S1K), they did not increase endurance exercise performance (Figure S1L).
 128 Due to this sexually dimorphic response, we exclusively used male mice for subsequent
 129 studies.

130 RER calculates substrate utilization during activity (Speakman, 2013) and a lower RER
 131 indicates increased reliance on fat oxidation. To directly measure substrate utilization during
 132 exercise, we performed a one-time endurance exercise test in metabolic treadmills, monitoring
 133 the RER continuously throughout the exercise bout. Consistent with our non-metabolic
 134 treadmill data, SAAR mice ran significantly longer (Figures S1M-N). At the terminal spike of
 135 the RER as the animals reach exhaustion, the RER was lower, indicating more fat utilization,
 136 in SAAR animals compared to controls (Figure 1H).



137 **Figure 1 Short-term SAAR induces shifts in metabolism and increases endurance**
 138 **exercise capacity in young, sedentary, male mice.**

139 A. Experimental set up and color scheme used throughout figure 1 and figure S1.

- 140 B. Body weight trajectory over time, shown as percent of starting body weight (n = 10) of
141 male mice given *ad libitum* access to sulfur amino acid restricted (SAAR) versus
142 control (Con) diet for seven days.
- 143 C. Food intake expressed as grams of food per gram of body weight per mouse within a
144 24 h period (n = 10) of male mice given *ad libitum* access to SAAR versus Con diet on
145 day seven.
- 146 D. Sable systems indirect calorimetry measurements of respiratory exchange ratios (CO₂
147 emission/O₂ consumption, VCO₂/VO₂, RER) over a 24 h period (n = 10) and
148 E. the average RER during a 12 h – 12 h light–dark cycle (n = 10/group) of male mice
149 given *ad libitum* access to SAAR versus Con diet on day seven.
- 150 F. The average wheel running in meter during a 12 h – 12 h light–dark cycle (n = 10) of
151 male mice given *ad libitum* access to SAAR versus Con diet on day seven.
- 152 G. Distance ran in meter during a one-time maximal endurance test (n = 20) of male mice
153 given *ad libitum* access to SAAR versus Con diet on day seven.
- 154 H. Quantification of RER at maximal exercise time, during a one-time maximal endurance
155 test, performed on a metabolic treadmill (Harvard Apparatus) (n = 10) of male mice
156 given *ad libitum* access to SAAR versus Con diet on day seven.
- 157


158 All data is shown as mean and error bars indicate SD unless otherwise noted; p values indicate
159 the significance of the difference by Student's t test or two-way ANOVA with Sidak's multiple
160 comparisons test between diets or diet and cycle (indirect calorimetry); significance is
161 determined by a p value of p < 0.05. Each dot represents an individual mouse. See also Figure
162 S1 and Table S1.

163 **Transcriptomics across muscle depots reveal metabolic shift from glycolytic** 164 **toward oxidative**

165 Little is known about the effects of SAAR on metabolic capacity in skeletal muscle. Most work
166 has focused on skeletal muscle after long-term SAAR, specifically insulin sensitivity or
167 alterations in skeletal muscle composition with SAAR in aged mice (Ghosh et al., 2017, 2014;
168 Swaminathan et al., 2021). Since our data suggests that seven days of SAAR is sufficient to
169 alter systemic metabolism, we aimed to further characterize metabolic changes in specific
170 skeletal muscles.

171 To investigate SAAR effects on skeletal muscle while accounting for fiber type, we compared
172 glycolytic EDL with oxidative soleus using bulk RNAseq (experimental scheme, Figure 2A).
173 Gene set overrepresentation analysis on genes affected by diet independent of muscle type
174 showed upregulation of pathways associated with fatty acid or organic acid catabolism and
175 muscle fiber type switching and downregulation of pathways associated with extracellular
176 matrix associated processes and collagen biosynthesis (Figure S2A). The expression of many
177 genes was coordinated in a fiber type dependent fashion (Figures S2B-C), so we investigated
178 expression changes after SAAR within EDL and soleus compared to control diet. Gene-level
179 analysis of fatty acid import and catabolic genes revealed consistently stronger effects in EDL
180 compared to soleus (Figure 2B). A validated ISR/SAAR target gene-set (Torrence et al., 2021)
181 revealed limited muscle type-specific responses, including in the ATF4 target *Cth* (Hine et al.,
182 2015) (Figure S2F). This indicated that depot-specific responses to SAAR are specific for fatty
183 acid metabolism associated genes and may be ISR-independent.

184 We next looked specifically for expression patterns that showed a diet-by-muscle depot
185 interaction. Significant positive interaction terms (enriched in EDL but not soleus after diet)
186 included the previously identified organic acid catabolic processes and β -oxidation, as well as



187 **Figure 2 Transcriptomics across muscle depots reveal metabolic shift from glycolytic**
 188 **toward oxidative**

189 A. Experimental set up and color scheme used throughout figure 2 and figure S2.

- 190 B. Fold changes of transcripts associated with fatty acid (FA) catabolism and transport as
191 identified in supplementary figure 2A in muscle of male mice (n = 6) given *ad libitum*
192 access to sulfur amino acid restricted (SAAR) versus control (Con) diet for seven days.
193 C. Pathway enrichment analysis of genes showing significant diet by muscle interaction
194 effects.
195 D. Fold changes (SAAR vs Con) of TCA cycle genes in EDL and soleus.
196 E. Representative blots of electron transport chain complexes and
197 F. quantification of relative protein abundance normalized to vinculin of SDHB for EDL
198 and soleus (n = 6) of male mice given *ad libitum* access to SAAR versus Con diet on
199 day seven.
200 G. Representative blots of CD36, LPL and PDK4 and vinculin (**top**) and quantification of
201 relative protein abundance normalized to vinculin of CD36, PDK4, and LPL (**bottom**)
202 in EDL (n = 6) of male mice given *ad libitum* access to SAAR versus Con diet on day
203 seven.
204 H. Representative blots of CD36, LPL and PDK4 and vinculin (**top**) and quantification of
205 relative protein abundance normalized to vinculin of CD36, PDK4, and LPL from blots
206 (**bottom**) in soleus (n = 6) of male mice given *ad libitum* access to SAAR versus Con
207 diet on day seven.


208 All data is shown as mean and error bars indicate SD unless otherwise noted; p values indicate
209 the significance of the difference by Student's t test between diets; significance is determined
210 by a p value of $p < 0.05$. See also Figure S2 and Table S2.

211 mitochondrial matrix, (Figure 2C) suggesting a transcriptomic shift of glycolytic EDL to a more
212 oxidative phenotype. TCA cycle enzymes showed similar muscle depot-specific responses on
213 the transcriptomic level (Figure 2D). We also confirmed transcriptomic changes at the protein
214 level, finding that seven days of SAAR was sufficient to increase electron transport chain
215 (ETC) complexes in both EDL and soleus (Figures 2E and S2D-E). The most pronounced
216 changes were observed in SHDB which was increased by approximately 50% after SAAR in
217 EDL (Figure 2F) consistent with changes observed at the transcript level.

218 To determine the overlap between transcriptional adaptation to endurance training and short-
219 term SAAR we compared the transcriptional response to either training or SAAR in gene sets
220 associated with oxidative phosphorylation, using a recently published dataset (Furrer et al.,
221 2023). Transcriptional regulation of both TCA cycle genes and mitochondrial matrix genes
222 showed overlapping patterns between training and EDL diet response, whereas this was not
223 observed to the same extent in the soleus diet response (Figures S2G-H).

224 We also assessed changes in the protein levels of metabolic enzymes regulating energy
225 homeostasis (CD36, PDK4 and LPL), that were upregulated at the transcriptomic level, using
226 western blot in both the EDL and soleus after seven days of SAAR. CD36 trended towards
227 significant increase after SAAR in EDL only, consistent with the transcriptomic data. LPL and
228 PDK4 showed non-significant increases after SAAR in EDL, however protein levels were
229 variable overall (Figure 2G). Neither CD36, LPL nor PDK4 showed changes after SAAR in
230 soleus (Figure 2H). These changes prompted us to investigate the functional relationship
231 between circulatory lipid turnover and handling.

232 SAAR increases muscle lipid flux without altering lipid pool sizes



233 Figure 3 SAAR increases muscle lipid flux without altering lipid pool sizes

234 A. Experimental design and color scheme used in figure 3A-E and figure S3A.

- 235 B. Circulatory carbon flux ($n = 10-13$) of $^{13}\text{C}_{18}$ -U-Linolate of jugular vein catheterized male
236 mice given *ad libitum* access to sulfur amino acid restricted (SAAR) versus control
237 (Con) diet for seven days.
- 238 C. *Ex vivo* β -oxidation measured by incorporation of ^3H -palmitic acid in ^3H - H_2O in muscles
239 of male mice fed a Con or SAAR diet for seven days ($n = 15$).
- 240 D. Representative fluorescence images (**left**) of BODIPY 493:503 (green), WGA647 (red)
241 and dapi (blue) staining in EDL cross-sections (scale bar, $50\ \mu\text{m}$) and quantification of
242 Bodipy⁺ Intensity within fibers (**right**) of male mice fed a Con or SAAR for seven days
243 ($n = 6$).
- 244 E. Lipidomics analysis from muscle of male mice fed a Con or SAAR diet for seven days
245 ($n = 6$), summarized as normalized ion counts of each main lipid class.
- 246 F. Experimental set up and color scheme used in figure 3 G-H and figure S3D-I.
- 247 G. Percent change in body weight ($n = 16$) of male WT and $\text{EC}^{\text{CD}36^{-/-}}$ mice given *ad libitum*
248 access to SAAR versus Con diet after seven days.
- 249 H. Distance ran during a one-time maximal endurance test ($n = 8$) of male WT and $\text{EC}^{\text{CD}36^{-/-}}$
250 $^{-/-}$ mice given *ad libitum* access to SAAR versus Con diet on day seven.

251 All data is shown as mean and error bars indicate SD unless otherwise noted; p values indicate
252 the significance of the difference by Student's t test between diets, or two-way ANOVA with
253 Sidak's multiple comparisons test between diets and muscle or genotype; significance is
254 determined by a p value of $p < 0.05$. See also Figure S3 and Table S3-5.

255 To test whether the transcript and protein level changes we observed (Figures 2B-H) resulted
256 in functional alterations in lipid metabolism, we measured the circulatory turnover flux (F_{circ}) of
257 linoleate in steady-state infusions (Hui et al., 2020) in jugular vein-catheterized mice after
258 seven days of SAAR (experimental scheme, Figure 3A). Linoleate turnover flux was
259 significantly increased after SAAR compared to control mice (Figure 3B). To test whether
260 skeletal muscle fatty acid consumption is involved in driving increased flux, we assessed *ex*
261 *vivo* skeletal muscle β -oxidation after short-term SAAR, using radiolabeled palmitate in EDL
262 and soleus. Across both muscle depots, there was a significant main effect of diet on β -
263 oxidation, however post-hoc tests revealed a significant control vs SAAR difference in EDL
264 only, highlighting the more pronounced shift of glycolytic muscle to increase lipid oxidation
265 (Figure 3C).

266 Increased lipid turnover and oxidation can be driven by two major mechanisms: increased
267 circulating lipid concentrations driving an increase in uptake and storage by mass action (Li et
268 al., 2022) or changes in lipid transporter activity. To test if mass action was driving increased
269 turnover and β -oxidation in the muscle, we first measured intramyocellular lipid storage after
270 seven days of diet. Bodipy staining in sections of EDL did not show increased intramyocellular
271 lipid storage between diet groups (Figure 3D). We also performed lipidomic and metabolomic
272 measurements to investigate changes in pool sizes of lipid classes and free fatty acid species
273 after SAAR in tissues. No major lipid classes in either EDL or soleus were affected by seven
274 days of SAAR compared to control (Figure 3E). When assessing differences driven by diet,
275 tissue, or diet and tissue interaction at an individual lipid species level, the dominant source of
276 variance was tissue. However, when focusing on the main effect of diet or diet-by-muscle
277 depot interaction effects, only a small number (3 and 16 respectively) out of 690 measured
278 lipid species were significantly changed (Supplemental Table 3). This trend was also generally
279 true for polar metabolites (Supplemental Table 4). Many metabolites showed significant main
280 effects of muscle depot, for example carnosine and anserine were enriched in glycolytic tissue

281 as previously reported (Luo et al., 2023) (Supplemental Table 4). We also observed a main
282 effect of diet in multiple metabolites associated with dietary protein restriction (ophthalmic acid)
283 (MacArthur et al., 2022) or *Pparg* associated changes in thermogenesis (aminoisobutyric acid)
284 (Roberts et al., 2014), however none of these changes showed diet by muscle depot
285 interaction effects. Downstream metabolites of the transsulfuration pathway (for example
286 taurine) were depleted in the muscle of mice on SAAR (Supplemental Table 4) suggesting
287 SAAR also affects metabolites downstream of methionine in the muscle. Overall, we did not
288 observe any changes due to diet in the pool-size of various free fatty acid species measured
289 in our metabolomic dataset (Figure S3A, supplemental table 4), suggesting that the increased
290 lipid turnover flux is not driven by an increase in lipid availability.


291 Movement of circulating fatty acids to the skeletal muscle requires their transfer across the EC
292 barrier and EC CD36 facilitates tissue fatty acid uptake (Peché et al., 2023; Son et al., 2018).
293 Since *Cd36* was upregulated by SAAR specifically in the EDL on both the transcriptomic and
294 protein level (Figures 2B,G-H), we tested a potential requirement for increased lipid shuttling
295 into the muscle via EC CD36. To explore this hypothesis, we generated a tamoxifen-inducible
296 EC specific CD36 knockout by crossing mice with a *Cd36* floxed allele with mice hemizygotously
297 expressing PDGF β iCre ($EC^{CD36^{-/-}}$) (Claxton et al., 2008). Cre⁺ and Cre⁻ litter mates were
298 distributed equally between control and SAAR group (experimental scheme, Figure 3F). One
299 cohort was used to study metabolic phenotypes and another was used to perform a one-time
300 endurance exercise test. The KO efficiency was confirmed by flow cytometry, gating for
301 CD31⁺CD36⁺ populations in both skeletal muscle and BAT (Figures S3B-E). EC^{Cd36} KO did
302 not affect the body weight changes induced by SAAR (Figures 3G and S3F). When performing
303 the endurance exercise capacity test, SAAR significantly increased running performance in
304 WT animals only. Post hoc testing showed increased running performance after SAAR in WT
305 animals and $EC^{CD36^{-/-}}$ deletion attenuated the running performance increases after SAAR
306 (Figure 3H). To test whether $EC^{CD36^{-/-}}$ had an effect on fatty acid composition in skeletal muscle
307 and circulation after one week of diet, we performed bulk metabolomics. After false-discovery
308 rate (FDR) correction, very few metabolites were significantly affected by genotype or diet in
309 EDL (13 and 7 respectively), soleus (3 and 3 respectively) or serum (16 and 28 respectively),
310 none of which showed consistency, likely due to high sample variability (Figures S3G-H,
311 supplementary table 5).

312 **FGF21 is dispensable for increased running capacity upon SAAR**

313 FGF21 plays a critical role in the systemic metabolic adaptations to SAAR and can drive
314 increased β -oxidation, particularly in adipose tissue (Agius et al., 2024; Forney et al., 2020;
315 Hill et al., 2019; Wanders et al., 2017). To test whether FGF21 is required for increased
316 running performance upon SAAR, mice with an *Fgf21* floxed allele were crossed with CMV-
317 Cre to achieve stable whole body *Fgf21* knock out (FGF21KO) (experimental scheme, Figure
318 4A). FGF21KO and WT littermates were evenly distributed between dietary groups with one
319 cohort used to assess metabolic changes and a second cohort for one time treadmill testing
320 after seven days of diet. No significant effects of genotype on SAAR-induced body weight
321 changes were observed (Figures 4B and S4A). However, in agreement with previous
322 observations, the decreased body weight in FGF21KO animals on SAAR can be mainly
323 explained by a decrease in food intake (Figure S4B) (Wanders et al., 2017). FGF21KO had
324 no effect on running performance, with both genotypes tending to increase after SAAR (Figure
325 4C). However, variability in the control groups limited these trends from reaching statistical

326 significance in either genotype (Figure 4C). KO efficiency was confirmed by serum FGF21
 327 ELISA, where SAAR increased circulating FGF21 levels, and no FGF21 was detected in
 328 serum of FGF21KO animals (Figure S4C).

329 We and others have observed increases in FGF21 after SAAR, therefore we tested whether
 330 FGF21 alone is sufficient to increase running performance by infusing recombinant FGF21 for
 331 seven days. We implanted WT C57BL/6J male mice with osmotic minipumps loaded with
 332 either saline solution or recombinant FGF21 (dosed at 1 mg/kg/day) for seven days
 333 (experimental scheme, Figure 4D). Expression of known FGF21 downstream targets in BAT
 334 were tested using qPCR to confirm the sufficiency of exogenous FGF21 to induce molecular
 335 changes. *Ucp1* and *Fgf21* were upregulated in both the exogenously supplied FGF21 group
 336 as well as the SAAR group (Figure S4E). Exogenous FGF21 caused a significant reduction in
 337 body weight, although to a lesser extent than what we observe with the SAAR diet (Figures
 338 4E and S4D). On day seven of the intervention the animals underwent a one-time treadmill
 339 test. Exogenous FGF21 supply was not sufficient to mimic SAAR in increasing endurance
 340 exercise capacity (Figure 4F). Taken together FGF21 is not necessary for the increased
 341 endurance exercise capacity after SAAR and is not sufficient to increase endurance exercise
 342 capacity on its own.



343 **Figure 4 FGF21 is dispensable for increased running capacity upon SAAR**

- 344 A. Experimental design and color scheme used in figure 4B-C and figure S4A-C.
 345 B. Percent change in body weight (n = 11 - 24) of male WT or FGF21KO mice given *ad libitum*
 346 access sulfur amino acid restricted (SAAR) versus control (Con) diet for seven
 347 days.
 348 C. Distance ran during a one-time maximal endurance test (n = 11 - 24) of male WT or
 349 FGF21KO mice given *ad libitum* access to SAAR versus Con diet on day seven.
 350 D. Experimental set up and color scheme used throughout E-F and figure S4D-E.

- 351 E. Percent change in body weight (n = 8) of NaCl or recombinant FGF21 treated male
352 mice for seven days.
353 F. Distance ran during a one-time maximal endurance test (n = 8) of NaCl or recombinant
354 FGF21 treated male mice on day seven.


355 All data is shown as mean and error bars indicate SD unless otherwise noted; p values indicate
356 the significance of the difference by Student's t test between treatments, or two-way ANOVA
357 with Sidak's multiple comparisons test between diets and genotype; significance is determined
358 by a p value of $p < 0.05$. See also Figure S4.

359 **Inhibition of VEGFR signaling blocks increased endurance exercise capacity by** 360 **SAAR**

361 Our previous work demonstrated that long-term SAAR increases EC VEGF levels and induces
362 angiogenesis in the muscle (Longchamp et al., 2018), which is crucial for exercise
363 performance (Delavar et al., 2014; Olfert et al., 2009). Therefore, we examined the
364 transcriptomic signature associated with VEGF-signaling in our RNA seq dataset. Interestingly
365 we observed that *Vegfb* was increased by SAAR specifically in the EDL (Figures 5A-B) and
366 *Flt1* (encoding VEGFR1) trended towards an increase in both EDL and soleus (Figures 5A,C).
367 *Vegfa* and *Kdr* (encoding VEGFR2) were not affected at the transcript level by short-term
368 SAAR (Figures S5A-B). To test whether induction of VEGF-dependent angiogenesis was a
369 driver of increased running capacity, we treated animals with the pan-VEGFR inhibitor axitinib
370 or vehicle control by oral gavage for the seven-day duration of the dietary intervention
371 (experimental scheme, Figure 5D). Treatment with axitinib did not affect the body weight
372 response to SAAR (Figures 5E and S5C). However, upon one-time endurance exercise testing
373 at day seven, axitinib blunted the increased running performance of SAAR mice (Figure 5F).
374 To test whether this was due to the prevention of SAAR-induced angiogenesis we measured
375 vascular density in the muscle. Immunofluorescent labeling of the vasculature in cryosections
376 of EDL did not show any significant changes in vascular area as a function of either SAAR or
377 axitinib treatment (Figures 5G and S5D). Labeling proliferating ECs using EdU also did not
378 show an effect of SAAR on EC proliferation in either EDL or soleus after seven days (Figure
379 S5E). Similarly, quantifying total CD31⁺ cells using FACS analysis, revealed no increase in
380 EC number after seven days of SAAR in either muscle or BAT (Figures S5F-G).

381 Since angiogenesis was not changed with axitinib treatment or short-term SAAR, we next
382 assessed whether transcriptional regulation of the VEGF/VEGFR genes were altered using
383 RNA sequencing of the EDL from mice treated with axitinib during seven days of SAAR. After
384 SAAR only in combined with axitinib treatment, *Vegfa* and *b* were increased, while the
385 induction of both receptors after short-term SAAR in combination with axitinib was prevented
386 (Figures 5H-I and S5H-I). Interestingly, we also observed that inhibition of VEGF-signaling
387 downregulated fatty acid transport associated transcripts (Figure S5J) but on the other hand
388 further promoted dietary increases in ETC associated genes (Figure S5K), suggesting that
389 VEGF signaling may control fatty acid availability but not oxidation capacity. To differentiate
390 between the different VEGFRs and their contribution to the endurance exercise capacity
391 increase we observed, we treated mice with DC101, a VEGFR2 specific antibody
392 (Arulanandam et al., 2015) or an IgG control and measured metabolic as well as exercise
393 parameters (experimental scheme, Figure 5J). Inhibiting VEGFR2 specifically with DC101, did
394 not alter the dietary effect of SAAR on either reducing body weight or increasing food intake
395 (Figures 5K and S5L-M). However, inhibiting VEGFR2 was sufficient to prevent the SAAR-

396 induced increase in endurance exercise capacity (Figure 5L). Taken together these data
 397 implicate a role for VEGF-signaling in modulating endurance exercise capacity after short-
 398 term SAAR.



399 **Figure 5 Inhibition of VEGFR signaling blocks increased endurance exercise capacity**
400 **by SAAR**

- 401 A. Fold changes of transcripts associated with Vegf signaling using transcriptomic dataset
402 presented in figure 2 in muscles of male mice (n = 6) after sulfur amino acid restriction
403 (SAAR) compared to control (Con) diet for seven days.
- 404 B. Normalized count values of Vegfb in EDL and soleus from bulkRNA sequencing (n =
405 6) of male mice given *ad libitum* access to SAAR versus Con diet on day seven.
- 406 C. Normalized count values of Flt1 in EDL and soleus from bulkRNA sequencing (n = 6)
407 of male mice given *ad libitum* access to SAAR versus Con diet on day seven.
- 408 D. Experimental set up and color scheme used in figure 5E-F and figure S5C-D.
- 409 E. Percent change in body weight (n = 16 - 24) of male mice treated with vehicle (veh) or
410 axitinib via oral gavage in combination with *ad libitum* access to SAAR versus Con diet
411 after seven days.
- 412 F. Distance ran during a one-time maximal endurance test (n = 16-24) of male mice
413 treated with veh or axitinib via oral gavage in combination with *ad libitum* access to
414 SAAR versus Con diet for seven days.
- 415 G. Representative fluorescence images of IB4 (white) staining in EDL cross-sections of
416 mice fed a Con or SAAR Diet, co-treated with veh or axitinib via oral gavage (scale
417 bar, 400 μ m) for seven days (n = 5-8).
- 418 H. Normalized count values of Vegfb in EDL treated with either veh or axitinib from
419 bulkRNA sequencing (n = 5) of male mice given *ad libitum* access to SAAR versus
420 Con diet on day seven.
- 421 I. Normalized count values of Flt1 in EDL treated with either veh or axitinib from bulkRNA
422 sequencing (n = 5) of male mice given *ad libitum* access to SAAR versus Con diet on
423 day seven.
- 424 J. Experimental set up and color scheme used in figure 5K - L and figure S5J - K.
- 425 K. Percent change in body weight (n = 8-10) of male mice treated with IgG or DC101 via
426 i.p. injection every other day in combination with *ad libitum* access to SAAR versus
427 Con diet after seven days.
- 428 L. Distance ran during a one-time maximal endurance test (n = 12-16) of male mice
429 treated with IgG or DC101 via i.p injection every other day in combination with *ad*
430 *libitum* access to SAAR versus Con diet on day seven.

431
432 All data is shown as mean and error bars indicate SD unless otherwise noted; p values indicate
433 the significance of the difference by two-way ANOVA with Sidak's multiple comparisons test
434 between diets and treatment; significance is determined by a p value of $p < 0.05$. See also
435 Figure S5 and Table S6.

436 **Discussion**

437 Using healthy, sedentary, male mice, we report that short-term sulfur amino acid restriction
438 rewires systemic and muscle metabolism and increases endurance exercise capacity
439 independently of angiogenesis, through noncanonical VEGF-signaling.

440 Little research has focused on the skeletal muscle functional outcome of the metabolic
441 changes after SAAR. In aged mice, 18 weeks of SAAR rescued lean mass losses upon age
442 but also prevented muscle hypertrophy after overload (Swaminathan et al., 2021). While

443 running performance or other indicators of muscle fitness were not assessed in that study, the
444 authors did show elevated levels of succinate dehydrogenase activity (SDH) suggesting
445 increased oxidative capacity after SAAR in skeletal muscle. Similar findings on citrate
446 synthase activity and mitochondrial biogenesis have also been observed (Perrone et al.,
447 2012). Functionally, it is widely established that SAAR increases EE (Forney et al., 2020;
448 Hasek et al., 2010; Perrone et al., 2010; Wanders et al., 2017; Yu et al., 2018), however little
449 research mentions whole body substrate utilization (RER) or physical activity. Increases in
450 total activity were measured after 8 weeks of SAAR feeding, where studies (Lees et al., 2014,
451 Yu et al., 2018) reported lowered RER after 5 weeks of a western diet restricted in sulfur amino
452 acids but these data could be influenced by different lipid compositions of the diet.

453 After seven days, we found that SAAR promoted a metabolic shift towards whole body fat
454 oxidation during rest as well as exercise measured by RER which was reflected by increased
455 expression of genes related to fat oxidation and oxidative phosphorylation in skeletal muscle.
456 Functionally, this increased whole body linolate F_{circ} and β -oxidation in skeletal muscle. The
457 activation of fat metabolism was more pronounced in muscle with a higher proportion of
458 glycolytic fibers, such as the EDL. However, we did observe increases in oxidative
459 phosphorylation genes in more oxidative muscles as well, and pathways associated with
460 increases in fatty acid catabolism and organic acid import were increased upon diet rather
461 than being specific for diet:muscle interaction. We thus hypothesize that due to the already
462 high fat oxidative capacity of oxidative muscles, changes in EDL are more prone to elicit
463 relevant changes on a functional level. Overall SAAR leads to an increase in oxidative capacity
464 and expression of genes involved in fatty acid catabolism and oxidation in all muscles.

465 Seven days of SAAR was sufficient to increase both circulatory fatty acid turn-over as well as
466 muscle specific β -oxidation. We did not see changes in either intramyocellular lipid storage or
467 changes in lipid composition or free fatty acid pool size upon the dietary treatment. This
468 suggests that the increase in fat oxidation was fueled by increased fatty acid uptake from the
469 circulation which requires transendothelial transport. Consistently, the expression and protein
470 content of the fatty acid transporter CD36 was increased upon SAAR. Restricting the acute
471 supply of fatty acid influx via endothelial CD36 deletion during exercise was enough to
472 attenuate the endurance exercise capacity phenotype. This underscores the importance of
473 fatty acid supply, in addition to oxidation, for SAAR to elicit its beneficial effects on endurance
474 exercise capacity. Of note, our observations that preventing transendothelial lipid transport
475 ablated the running phenotype demonstrates necessity, but not sufficiency of CD36 for
476 increasing running performance. However, increased lipid uptake upon SAAR is required to
477 fuel oxidative phosphorylation, and whether or not inhibition of oxidative phosphorylation also
478 attenuates the endurance exercise capacity is yet to be tested.

479 Previously we have shown that long-term SAAR drives angiogenesis in skeletal muscle via
480 activating VEGF-signaling in ECs, leading to increased vascular density (Longchamp et al.,
481 2018). In this study, one week was not sufficient to stimulate neovascularization in the muscle
482 and is consistent with the timeline for neovascularization following exercise training, which
483 requires 2-3 weeks of consistent training for an observable increase in vascular density (Bloor,
484 2005). We also did not observe an increase in endothelial cell proliferation. We therefore
485 propose that the improved endurance exercise capacity upon SAAR is driven by a metabolic
486 shift favoring fatty acid transport by ECs and oxidation by skeletal muscle rather than by
487 increased muscle vascularization. Interestingly, inhibition of pan VEGFRs or VEGFR2 alone

488 also inhibited the endurance exercise capacity increase upon SAAR implicating a role of
489 VEGF-signaling on SAAR's effect on endurance exercise capacity independent of its
490 canonical role in angiogenesis. Our transcriptomic dataset after SAAR and axitinib treatment
491 suggests that the effect of inhibiting VEGF-signaling mainly acts on fatty acid uptake as ETC
492 associated genes and genes involved in fatty acid oxidation remained upregulated.
493 Angiogenesis driven by longer-term SAAR treatment could possibly augment the increased
494 endurance exercise performance further and could be tested in future studies.

495 Previous studies have shown that VEGF-dependent activation of AKT and AMPK is required
496 for EC proliferation (Nagata et al., 2003; Reihill et al., 2011; Stahmann et al., 2010). AMPK
497 has also been identified as a potential trigger for CD36 translocation (Han et al., 2019) and
498 AMPK is known to induce and upregulate fatty acid oxidation via oxidative phosphorylation in
499 the muscle (Han et al., 2019; Salminen et al., 2017). SAAR studies have shown that SAAR
500 activates AMPK via upregulation of H₂S in a VEGF-dependent fashion in the endothelium
501 (Longchamp et al., 2018), and more recent work established a role for an H₂S - AMPK axis in
502 chicken muscle (Li et al., 2023). Induction of H₂S by dietary restriction is widely established
503 (Hine et al., 2015; Jonsson et al., 2021; Zivanovic et al., 2019), and we too observed
504 transcriptional upregulation of *Cth* - a major enzymatic contributor to endogenous H₂S
505 production in muscle. Even though we did not further investigate AMPKs role in increasing
506 endurance exercise after short-term SAAR, AMPK could be a potential signaling hub
507 integrating upstream VEGF-signaling with downstream upregulation of oxidative
508 phosphorylation and increased fatty acid uptake. A potential signaling cascade could include
509 EC VEGF - ATF4 - H₂S - AMPK - CD36 signaling resulting in increased fatty acid import into
510 the muscle via the endothelium, allowing for increased systemic turnover, and at the same
511 time promoting β -oxidation in the muscle thereby increasing endurance capacity in sedentary
512 male mice. Previous studies have focused on EC intrinsic VEGF-signaling, showing
513 upregulation of the VEGF - ATF4 - H₂S - AMPK in ECs but not in the whole muscle tissue.
514 Based on our data, we cannot exclude VEGF-driven metabolic crosstalk between EC and
515 myofibers upon SAAR.

516 **Limitation of this study**

517 Due to technical limitations, we were unable to unravel the specific contribution of VEGF-A or
518 -B as the molecular driver of endurance exercise capacity increases after short-term SAAR.
519 We found that both VEGF-A as well as VEGF-B are transcriptionally upregulated after dietary
520 SAAR. Inhibition of VEGFR2, which exclusively binds VEGF-A, prevented increased running
521 performance, suggesting a causal role for VEGF-A and its receptor. Skeletal muscle VEGF
522 has been reported to be crucial for exercise training, as deletion of VEGF blunted exercise
523 capacity in mice (Delavar et al., 2014). We and others have previously shown that SAAR
524 increases endothelial VEGF signaling (Das et al., 2018; Longchamp et al., 2018). However,
525 an increase in VEGF-B could still push increased VEGF-A/VEGFR2 interaction due to
526 competition for VEGFR1 binding. Further research and genetic models will be required to
527 completely address this question.

528

529 **Acknowledgements/Funding**

530 This work was supported by the National Institute on Aging (P01AG055369 to SJM), an ETH
531 Zurich Doc.Mobility Fellowship (CGM) and ETH Zurich core funding. We dedicate this work to
532 our late mentor and friend, James R Mitchell. We want to thank the center of PhenoGenomics
533 at EPFL for helping us perform the metabolic running experiments.

534 **Author Contributions**

535 Conceptualization, C.G.M., M.R.M., K.D.B., J.R.M, and S.J.M.; Methodology, C.G.M., M.R.M.,
536 J.Z., S.G., J.E.A., W.L., C.H., T.A.; Resources, A.L., F.A., J.R., K.D.B and S.J.M; Writing,
537 C.G.M., M.R.M., K.D.B., and S.J.M.; Funding Acquisition, C.G.M, M.R.M and S.J.M.

538 **Declaration Of Interests**

539 The authors declare no competing interests.

540

541 **STAR Methods**

542 **RESOURCE AVAILABILITY**

543 **Lead Contact.** Further information and requests for resources and reagents should be
544 directed to and will be fulfilled by the Lead Contact, Sarah Mitchell (sm3272@princeton.edu).

545
546 **Materials Availability.** Reagents used to conduct the research detailed in this manuscript are
547 available on request from the Lead Contact, Sarah Mitchell (sm3272@princeton.edu).

548
549 **Data and Code availability.** The authors declare that all the data supporting the findings of
550 this study are available within the article and its Supplementary Information Files.

551

552

553 **KEY RESOURCES TABLE**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Goat anti-Mouse/Rat CD31/PECAM-1 antibody	R&D Systems	Cat# 3628; RRID: AB 2161028
Rat anti-CD31 antibody	Abcam	Cat# ab7388; RRID: AB 305905
PE Rat Anti-Mouse CD31	BD Biosciences	Cat# 553373; RRID: AB 394815
PerCP Rat Anti-Mouse CD45	BD Biosciences	Cat# 557235; RRID: AB 10642171
Mouse (IgG2b) Myosin Heavy Chain Type I antibody (BA-F8)	DSHB	Cat# BA-F8; RRID: AB 10572253
Mouse (IgG1) Myosin Heavy Chain Type IIA antibody (SC-71)	DSHB	Cat# SC-71; RRID: AB 2147165
Mouse (IgM) Myosin Heavy Chain Type IIB antibody (BF-F3)	DSHB	Cat# BF-F3; RRID: AB 2266724
Total OXPHOS Rodent WB Antibody Cocktail	Abcam	Cat# ab110413; RRID: AB 2629281
PE Hamster Anti-Mouse CD36	BioLegend	Cat# 102605; RRID: AB 389349
Rabbit anti-CD36 antibody	Abcam	Cat# ab124515; RRID: AB 2924667
Rabbit anti-PDK4 antibody	Abcam	Cat# ab214938; RRID: AB 2864318
Goat anti Human/Mouse Lipoprotein lipase antibody	R&D Systems	Cat# AF7197; RRID:

		AB 10972480
Wheat Germ Agglutinin (WGA)	Thermo Fisher Scientific	Cat# W11262
IRDye 800RD Goat anti-Mouse IgG (H+L)	LI-COR BioScience	Cat# LIC-926-68070
IRDye 680RD Goat anti-Rabbit IgG (H + L) Highly Cross-Adsorbed	LI-COR BioScience	Cat# LIC-926-68071
Anti-rabbit IgG, HRP-linked	Cell Signaling	Cat# 7074
Goat anti-Mouse IgG2b Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 488	Thermo Fisher Scientific	Cat# A-21141
Goat anti-Mouse IgG1 Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 350	Thermo Fisher Scientific	Cat# A-211120
Goat anti-Mouse IgGM (Heavy Chain) Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 568	Thermo Fisher Scientific	Cat# A-21043
Chemicals, peptides, and recombinant proteins		
Collagenase IV	Thermo Fisher Scientific	Cat# 17104019
Dispase II	Sigma-Aldrich	Cat# D4693
Hoechst	Thermo Fisher Scientific	Cat# 62249
5-Ethynyl-2'-deoxyuridine (EdU)	Thermo Fisher Scientific	Cat# C10632/4
Alexa-647 Fluor conjugated isolectin B4	Thermo Fisher Scientific	Cat# I32450
Tamoxifen	Sigma-Aldrich	Cat# T5648
Axitinib	MedChemExpress	Cat# HY-10065
InVivoMAb rat IgG1 isotype control	BIOZOL	Cat# BXC-BE0088
InVivo MAb anti Mouse VEGFR- 2, Clone: [DC101], Rat, Monoclonal	BIOZOL	Cat# BXC-BE0060
Linoleic Acid (18:2), sodium salt (U- ¹³ C ₁₈ , 98%)	Cambridge Isotope Laboratories	Cat# CLM-10487-PK
Palmitic Acid, [9,10- ³ H(N)]-, 1mCi, (37MBq)	Perkin Elmer	Cat# NET043001MC
BODIPY™ 493/503	Thermo Fisher Scientific	Cat# D2191
mouse recombinant FGF21	Preprotech	Cat# 450-56
Critical commercial assays		
Pierce BCA Protein Assay Kit	Thermo Fisher Scientific	Cat# 23225
mVEGF Elisa	R&D Systems	Cat# MMV00
mVEGFB Elisa	Abcam	Cat# ab289700
mFGF21 Elisa	R&D Systems	Cat# MF2100
RNeasy Kit	QIAGEN	Cat# 74034
High Capacity cDNA Reverse Transcription Kit	Thermo Fisher Scientific	Cat# 43-688-13
SYBRGreen-based Master Mix	Thermo Fisher Scientific	Cat# A25778
Click-iT Cell Reaction Buffer Kit	Thermo Fisher Scientific	Cat# C10269

Deposited data		
Muscle transcriptomics raw and analyzed	This paper	Table S2 and 6
Muscle lipidomics	This paper	Table S3
Muscle and plasma metabolomics from WT and WT and CD36 ^{EC-/-} mice	This paper	Table S4-5
Experimental models: Organisms/strains		
Mouse: C57BL/6J wild type	Charles River Laboratories	N/A
Mouse: CD36 ^{fl/fl}	Charles River Laboratories	N/A
Mouse: <i>fgf21</i> ^{fl/fl}	Charles River Laboratories	N/A
Mouse: <i>pdgfb</i> -Cre ^{ERT2}	(Claxton et al., 2008)	N/A
Oligonucleotides		
<i>Fgf21</i> : F: CAAATCCTGGGTGTCAAAGC	N/A	N/A
<i>Fgf21</i> : R: CATGGGCTTCAGACTGGTAC	N/A	N/A
<i>Ucp1</i> : F: GCATTCAGAGGCAAATCAGC	N/A	N/A
<i>Ucp1</i> : R: GCCACACCTCCAGTCATTAAG	N/A	N/A
<i>18s</i> : F CATGCAGAACCCACGACAGTA	N/A	N/A
<i>18s</i> : R CCTCACGCAGCTTGTGTCTA	N/A	N/A
<i>Actin</i> : F AGCTTCTTTGCAGCTCCTTCGTTG	N/A	N/A
<i>Actin</i> : R TTCTGACCCATTCCCACCATCACA	N/A	N/A
Software and algorithms		
FlowJo Software (version 10.4.2)	Three Star	https://www.flowjo.com/
ImageJ (for image analysis)	NIH	https://imagej.nih.gov/ij/
Prism 8 (version 8.0.0)	GraphPad Software	https://www.graphpad.com/scientific-software/prism/
Adobe Illustrator CS6 (version 16.0.4)	Adobe	https://www.adobe.com/
R 4.0.3	cran.r-project	https://cran.r-project.org/bin/windows/base/
El Maven	Elucidata	https://github.com/ElucidataInc/ElMaven/releases

554

555 EXPERIMENTAL MODELS

556 EXPERIMENTAL MODEL AND STUDY DETAILS

557 Mice

558 All animal experiments were approved by the local animal ethics committees (Kantonales
559 Veterinäramt Zürich, licenses ZH211/19, ZH149/21, ZH133/23, Animal Care and Use
560 Committee for Princeton University, Harvard Medical Area or Boston University Institutional
561 Animal Care and Use Committee (IACUC) and Service de la Consommation et des Affaires

562 Vétérinaires SCAV-EXPANIM, license VD-3664), and performed according to local guidelines
563 (TschV, Zurich) and the Swiss animal protection law (TschG). Health status of all mouse lines
564 was regularly monitored according to FELASA guidelines. Mice used in experiments were 8
565 to 14 weeks old. Mice were housed in standard housing conditions (22 C, 12 h light/dark cycle),
566 with *ad libitum* (AL) access to chow diet (18 % protein, 4.5 % fat, #3437, Provimi Kliba SA)
567 and water.

568 Wild type (WT) C57BL/6J and *Cd36* LoxP/LoxP mice (*Cd36^{tm1.1lg}/J*) were purchased from
569 Charles River (Freiburg im Breisgau, Germany). To obtain inducible endothelial cell-specific
570 *Cd36* knockout (*EC^{Cd36^{-/-}}*) mice, *Cd36* LoxP/LoxP mice were crossed with *PDGFβ.iCreER*
571 mice, an EC-selective inducible Cre-driver line (Claxton et al., 2008). Recombination was
572 induced in 8-10 weeks old male mice by daily intraperitoneal (i.p.) administration of 1mg
573 tamoxifen (T5648, Sigma-Aldrich) dissolved in 1:10 ethanol:corn oil solution for 3 consecutive
574 days. A wash out period of at least seven days was allowed before starting the experiments.
575 Tamoxifen-treated Cre-negative littermates were used as control for all experiments. *Fgf21*
576 knockout (*Fgf21KO*) mice were generated by crossing *Fgf21LoxP/LoxP* mice
577 (B6.129S6(SJL)-*Fgf21tm1.2Djm*/J) with loxP sites flanking exons 1-3 of the *Fgf21* gene with
578 CMV-Cre expressing mice (B6.C-Tg(CMV-Cre)1Cgn/J). The resulting offspring had a deletion
579 in exons 1-3 of *Fgf21* in all tissues. The line was subsequently maintained by breeding animals
580 heterozygous for the deletion allele.

581 Mouse recombinant FGF21 (Cat# 450-56, Peprotech) was dissolved and diluted in sterile
582 distilled water to a final dosage of 1 mg/kg/day. The filled 1007D Alzet osmotic minipump was
583 pre-soaked for 24 hours in NaCl at 37 °C in a dry incubator. Mice were anesthetized with 3%
584 isoflurane in 2 L O₂ and kept at 37 °C with an electrical heating pad. A 1-cm incision was
585 made in the skin of the upper back/neck to implant the sterile, preloaded minipump. 5-0
586 Prolene surgical suture was used to close the wound. Mice received paracetamol (2mg/ml
587 Dafalgan, UPSA) in the drinking water for 48 hours postoperatively.

588 Aseptic surgery was performed to place catheters in the right jugular vein connected to a
589 vascular access button implanted under the skin on the back of the mouse (Instech
590 Laboratories). Mice were allowed to recover from catheterization surgery for at least 5 days
591 before experimentation. Mice with catheters were individually housed in environmentally
592 enriched cages with AL access to water and food. Catheters were flushed with sterile saline
593 and refilled with sterile heparin glycerol locking solution (SAI Infusion Technologies, HGS)
594 every 5-6 days.

595 Experimental diets were based on Research Diets D12450J with approximately 18% of
596 calories from protein, 10% from fat and 72% from carbohydrates. SAAR diets containing 1.15g
597 methionine (M)/kg food and lacking cysteine (C) (Miller et al., 2005) in the context of a 17%
598 protein/ 73% carbohydrate calorie diet were provided AL. Food intake was monitored daily
599 during experiments. The Research Diets product number for the control diet is A17101101
600 and for SAAR diet is A17101103.

601 Where indicated, axitinib was delivered via daily oral gavage at a dose of 25 mg/kg in 0.5%
602 carboxymethylcellulose vehicle. To block VEGF/VEGFR2 signaling, mice were treated with
603 DC101, a rat monoclonal IgG1 antibody against VEGFR2 (30 µg/kg, i.p., BioXcell) every other
604 day for the duration of the dietary intervention.

605 To label proliferating cells, an i.p. injection of 5-ethynyl-2'-deoxyuridine (EdU) (E10187,
606 Thermo Fisher Scientific) solution (5 mg/ml in saline, 10 µl/g BW injected) was performed
607 seven hours before sacrificing the mice.

608 **METHOD DETAILS**

609 **Exercise experiments**

610 For endurance exercise capacity testing, mice were acclimated to a treadmill system for 3
611 sessions (5-lane treadmill, Harvard Apparatus, Panlab) before exercise capacity testing.
612 During acclimation sessions each animal ran for 10 min, increasing the speed from 5 m/min
613 up to 10 m/min at minute 5 and kept constant at 10 m/min for 5 min. Thereafter the animal
614 rested for 5 min, followed by 10 min at 10m/min with 5% incline. Following acclimation, mice
615 underwent an aerobic exercise capacity test to exhaustion on a treadmill with 5 degree angle.
616 Mice were motivated to run with a shock grid set at 0.2 mA. Starting speed was 5 m/min for 5
617 min and was increased by 1 m/min until exhaustion. Speed was capped at a maximum of 20
618 m/min until exhaustion. Current was taken off the grid, after mice received 10 shocks.
619 Treadmill session was terminated if the mice failed to return to the treadmill after 3 consecutive
620 attempts within the last minute of running. Aerobic capacity is expressed as total time or
621 distance run (m) during the test. During metabolic treadmill experiments, the same protocol
622 was followed but using Columbus Instruments metabolic treadmills to allow for measurement
623 of gas exchange during the exercise testing.

624 **Metabolic Cages**

625 Throughout the calorimetry studies, a standard 12-hour light/dark cycle was maintained. Prior
626 to data collection, all animals were weighed and acclimated to either control or SAAR diet for
627 three days. Mice were placed in metabolic cages, and measurements began for seven
628 consecutive days. Energy expenditure was determined using a computer-controlled indirect
629 calorimetry system (PromethionH, Sable Systems, Las Vegas, NV) as published (Grobe,
630 2017). Animals had unlimited access to food and water throughout the study. XYZ beam
631 arrays (BXYZ-R, Sable Systems, Las Vegas, NV) were used to record ambulatory activity and
632 position, and respiratory gasses were measured using an integrated fuel cell oxygen analyzer,
633 a spectro-photometric CO₂ analyzer, and a capacitive water vapor partial pressure analyzer
634 (GA3, Sable Systems, Las Vegas, NV). Oxygen consumption and CO₂ production were
635 monitored for 1-minute at 5-minute intervals. The respiratory quotient (RQ) was determined
636 by dividing CO₂ production by O₂ consumption. The Weir equation was used to calculate
637 energy expenditure: $\text{Kcal/hr} = 60 \cdot (0.003941 \cdot \text{VO}_2 + 0.001106 \cdot \text{VCO}_2)$. MetaScreen v. 2.5 was
638 used to coordinate data acquisition and instrument control, and raw data was processed using
639 ExpeData v. 1.8.5 (Sable Systems, Las Vegas, NV) via an analysis macro that detailed all
640 aspects of data transformation.

641 **Body composition and Food Intake**

642 Body mass was determined by daily measurement at approximately ZT22. Lean and fat mass
643 were measured in awake mice using an EchoMRI 100H body composition analyzer.

644 **RNA Extraction and Quantitative RT-PCR**

645 RNA of tissues was extracted using a RNeasy Kit according to the manufacturer's instructions
646 (QIAGEN, 74034). RNA purity and concentration were assessed via a spectrophotometer
647 (Tecan, Spark or NanoDrop, ThermoFisher). RNA was reverse-transcribed to cDNA by High
648 Capacity cDNA Reverse Transcription Kit (Thermo Fisher, 43-688-13). A SYBR Green-based

649 master mix (ThermoFisher Scientific, A25778) was used for real-time qPCR analysis with
650 primers listed in Table S2. To compensate for variations in RNA input and efficiency of reverse-
651 transcription, RPLP and Actin were used as a housekeeping gene. The delta-delta CT method
652 was used to normalize the data.

653 **RNA Sequencing and Differential Gene Expression Analysis**

654 RNA sequencing was performed by Novogene. The quality and quantity of isolated RNA and
655 final libraries were determined using Qubit Fluorometer and TapeStation (Agilent, Waldbronn,
656 Germany). Sequencing libraries were prepared following SMARTer[®] Universal Low Input
657 RNA Kit for Sequencing. Briefly, total RNA samples (0.25–10 ng) were reverse-transcribed
658 using random priming into double-stranded cDNA in the presence of a template switch oligo
659 (TSO). Ribosomal cDNA was cleaved by ZapR in the presence of the mammalian-specific R-
660 Probes. Remaining fragments were enriched with a second round of PCR amplification using
661 primers designed to match Illumina adapters. The product is a smear with an average
662 fragment size of approximately 360 bp. The libraries were normalized to 10nM in Tris-Cl 10
663 mM, pH8.5 with 0.1% Tween 20. Read quality was assessed using FastQC. Alignment to the
664 GRCm38 mouse reference genome was performed using the align function and annotation
665 was performed using the featureCounts function from the Rsubread package (Liao et al.,
666 2019). Genes were filtered based on minimum expression (> 5 counts per million in at least 5
667 samples). Differential gene expression was computed using a negative binomial model
668 implemented in the DESeq and limma packages (Love et al., 2014; Ritchie et al., 2015).
669 Significantly differentially expressed genes were defined as a p-value < 0.01 with a false
670 discovery ratio (FDR) < 0.1. FDR values were calculated using the Benjamini–Hochberg
671 method. Gene ontology enrePathway analysis was performed using the clusterProfiler R
672 package (Wu et al., 2021). Over-representation analysis was performed using the differentially
673 expressed genes (DEGs). Geneset-enrichment was performed using 3 databases: GO
674 Biological process (BP), KEGG pathway and Reactome pathway. P-values were corrected for
675 multiple testing using the Benjamini-Hochberg procedure and adjusted p-values < 0.05 were
676 considered significant. Complex heatmaps were generated using the ComplexHeatmap
677 package for R (Gu, 2022).

678 **Immunoblot Analysis**

679 Tissues were collected and lysed with [50 mM Tris–HCl pH 7.0, 270 mM sucrose, 5 mM EGTA,
680 1 mM EDTA, 1 mM sodium orthovanadate, 50 mM glycerophosphate, 5 mM sodium
681 pyrophosphate, 50 mM sodium fluoride, 1 mM DTT, 0.1% Triton X-100 and a complete
682 protease inhibitor tablet (Roche Applied Science)]. Lysates were centrifuged at 10000 g for 10
683 min at 4C. Supernatant was collected, and protein concentration was measured using the
684 Pierce BCA protein assay kit (23225, ThermoFisher Scientific). 5-10 mg of total protein was
685 loaded in a 15-well precast, gradient gel (456-8086, Bio-Rad). Proteins were transferred onto
686 a PVDF membrane (Bio-rad, 170-4156) with a semi-dry or wet system and subsequently
687 blocked for 1 h at room temperature with 5% milk in 0.1% TBS-Tween. Membranes were
688 incubated overnight at 4C with primary antibodies listed in Key Resources Table. The
689 appropriate HRP-linked secondary antibodies (see Key Resources Table) were used for
690 chemiluminescent detection of proteins. Membranes were scanned with a Chemidoc imaging
691 system (Bio-rad) and quantified using ImageJ software.

692 **Immunohistochemistry and Histology**

693 EDL or soleus muscle samples were harvested and embedded in Tissue-Tek and frozen in
694 liquid N₂-cooled isopentane and stored at -80 C until further use. Frozen muscle cross sections
695 (7-10 μm) were made using a cryostat (Leica CM 1950) and collected on Superfrost Ultra Plus
696 slides (Thermo Fisher Scientific). After acclimatizing to room temperature for approximately
697 15 min, skeletal muscle cryosections (10 μm) were fixed in 4% PFA for 10 min, washed three
698 times with PBS and subsequently incubated for 1 h in blocking buffer (PBS with 10% donkey
699 serum) at room temperature. Thereafter, samples were incubated overnight at 4C with primary
700 antibodies diluted in blocking buffer with or without addition of 0.1% Triton X-100. Slides were
701 subsequently washed in PBS and incubated for 1 h in blocking buffer with the appropriate
702 secondary antibodies at 1:250 dilution. Nuclei were stained with Hoechst.

703 Images were captured with a Zeiss Axio observer Z.1 or an Olympus confocal microscope
704 (FV1200). Fiber cross-sectional area was automatically determined on laminin-stained
705 sections with the Muscle J plugin for ImageJ software (Mayeuf-Louchart et al., 2018). In the
706 axitinib experiment, vascular density (% CD31+ area) was quantified within the whole tissue
707 with ImageJ software after threshold processing on 20x images acquired with a Nikon Eclipse
708 Ti2 microscope.

709 **Stable isotope infusions in mice**

710 For intravenous infusions, U-¹³C₁₈-Linolate (Cambridge Isotope Laboratories) was prepared at
711 a 2mM concentration in saline + 1mM BSA. Mice underwent surgery to insert a jugular vein
712 catheter and were allowed to recover for at least one week before experiments. The infusion
713 setup (Instech Laboratories) included a swivel and tether to allow the mouse to move around
714 the cage freely. Infusion rate was set to 0.3 μL/min and tracer infused for 90 minutes followed
715 by tail blood collection and tissue harvesting. Fasted infusions were collected at 5PM 8 hours
716 after chow removal (started infusion at 2:30PM).

717 **Metabolite extraction of serum**

718 Serum (3 μl) was extracted with cold 100% methanol (40X), vortexed, and incubated on dry
719 ice for 30 min. Then, the extract was centrifuged at 20,000 x g for 20 minutes at 4°C and
720 supernatant was transferred to tubes containing -fold excess 100% methanol, vortexed and
721 incubated on dry ice for 30 min. Then, the extract was centrifuged at 20,000 x g for 20 minutes
722 at 4°C and supernatant was transferred to tubes for LC-MS analysis.

723 **Metabolite extraction of tissues**

724 Frozen tissue pieces were pulverized using a Cryomill (Retsch) at cryogenic temperature.
725 Ground tissue was weighed (10–20 mg) and transferred into a precooled tube for extraction.
726 Soluble metabolites extraction was done by adding -20 °C 40:40:20
727 methanol:acetonitrile:water to the resulting powder (40 μl solvent per mg tissue). Samples
728 were vortexed for 10 seconds, cooled at 4°C (on wet ice) for 20 minutes and then centrifuged
729 at 4 °C at 20,000 x g for 30 minutes. Supernatant was transferred to LC–MS vials for analysis.

730 **Metabolite measurement by LC-MS**

731 LC-MS analysis for soluble metabolites was achieved on a quadrupole-orbitrap mass
732 spectrometer (Thermo Scientific): the Q Exactive PLUS hybrid, Exploris 240 or Exploris 480.
733 Each mass spectrometer was coupled to hydrophilic interaction chromatography (HILIC) via
734 electrospray ionization. To perform the LC separation of serum and tissue samples, an
735 XBridge BEH Amide column (150 mm × 2.1 mm, 2.5 μM particle size, Waters) was used with
736 a gradient of solvent A (95%:5% H₂O: acetonitrile with 20 mM ammonium acetate, 20 mM
737 ammonium hydroxide, pH 9.4), and solvent B (100% acetonitrile). The gradient was 0 minutes,
738 85% B; 2 minutes, 85% B; 3 minutes, 80% B; 5 minutes, 80% B; 6 minutes, 75% B; 7 minutes,
739 75% B; 8 minutes, 70% B; 9 minutes, 70% B; 10 minutes, 50% B; 12 minutes, 50% B; 13
740 minutes, 25% B; 16 minutes, 25% B; 18 minutes, 0% B; 23 minutes, 0% B; 24 minutes, 85%
741 B; 30 minutes, 85% B. The flow rate was 150 μl min⁻¹, an injection volume of 10 μl for serum
742 samples and 5 μl for tissue samples, and column temperature was 25°C. MS full scans were
743 in negative or positive ion mode with a resolution of 140,000 at *m/z* 200 and scan range of
744 70–1,000 *m/z*. The automatic gain control (AGC) target was 1 × 10⁶. LC-MS peak files were
745 analyzed and visualized with EI-MAVEN (Elucidata) using 5 ppm ion extraction window,
746 minimum peak intensity of 1 × 10⁵ ions, and minimum signal to background blank ratio of 2.
747 For infusion experiments, the software package Accucor was used to correct for metabolite
748 labeling from natural isotope abundance.

749 **Circulating flux measurements**

750 To measure the circulating (whole-body) flux of a metabolite, we infused U¹³C-labeled form of
751 the metabolite. At pseudo-steady state, we measured the mass isotope distribution of the
752 metabolite in serum and the intact tracer circulatory flux (F_{circ}) was calculated as previously
753 described. The fraction of the fully labeled tracer (i.e., the infused form), L_{M+C} (for example,
754 linolate is M+18 due to having 18 carbon atoms) was used:

$$755 \quad F_{circ} = R \cdot L_{[M + C]} / L_{[M + C]} \quad \text{(Equation 1)}$$

756 where R is the infusion rate of the labeled tracer. Since the circulatory flux is a pseudo-steady
757 state measurement, for minimally perturbative tracer infusions, production flux is
758 approximately equal to consumption flux of the metabolite and thus F_{circ} reflects both the
759 circulating production and consumption fluxes of the infused metabolite.

760 **Lipid extraction of tissues**

761 Frozen tissue pieces were pulverized using a Cryomill (Retsch) at cryogenic temperature.
762 Soluble lipid extraction was done by adding 50% methanol:50% H₂O and chloroform 2:1 to
763 the samples. Samples were incubated at 4°C (on wet ice) for 10 min and then centrifuged at
764 4 °C at 20,000 × *g* for 5 min. The bottom layer was extracted using glass hamilton syringes
765 and transferred to glass vials for further processing. The first extraction step was repeated and
766 the chloroform was evaporated using a nitrogen gas manifold. Samples were reconstituted in
767 1:1:1 methanol, acetonitrile, isopropyl alcohol for analysis.

768 **Lipid measurement by LC-MS**

769 Lipids were analyzed using a Vanquish Horizon UHPLC System (Thermo Scientific) coupled
770 to a Q Exactive Plus mass spectrometer (Thermo Scientific). Agilent Poroshell 120 EC-C18
771 column (particle size, 2.7 μm; 150 mm (length) × 2.1 mm (i.d.)) was used for separation.

772 Column temperature was 25 °C. Mobile phases A = 1 mM ammonium acetate and 0.2% (v/v)
773 acetic acid in 90:10 (v/v) water:methanol and B = 1 mM ammonium acetate and 0.2% (v/v)
774 acetic acid in 98:2 (v/v) isopropanol:methanol were used for ESI positive mode. The linear
775 gradient eluted from 25% B (0.0–2.0 min), 25% B to 65% B (2.0–4.0 min), 65% B to 100% B
776 (4.0–16.0 min), 100% B (16.0–20.0 min), 100% B to 25% B (20.0–21.0 min), 25% (21.0 – 25.0
777 min). The flow rate was 0.15 mL/min. The sample injection volume was 5 µL. ESI source
778 parameters were as follows: spray voltage, 3200 V or –2800 V, in positive or negative modes,
779 respectively (arb = arbitrary units); sheath gas, 35 arb; aux gas, 10 arb; sweep gas, 0.5 arb;
780 ion transfer tube temperature, 300 °C; vaporizer temperature, 35 °C. LC–MS data acquisition
781 was operated under full scan positive mode for all samples. The full scan was set as: orbitrap
782 resolution, 70,000 at m/z 200; AGC target, 3e6 arb; maximum injection time, 250 ms; scan
783 range, 265–1150 m/z. LC-MS peak files were analyzed and visualized with EI-MAVEN
784 (Elucidata) using 5 ppm ion extraction window, minimum peak intensity of 1×10^5 ions, and
785 minimum signal to background blank ratio of 2. For infusion experiments, the software
786 package Accucor was used to correct for metabolite labeling from natural isotope abundance.
787

788 **Ex vivo beta oxidation**

789 After seven-day dietary treatment mice fed either a Con or SAAR diet were sacrificed and EDL
790 and soleus dissected, weighed and immediately put on ice in low glucose DMEM (Thermo
791 Fisher Scientific). To start the assay, muscles are transferred to low glucose DMEM media
792 containing 2% fatty acid free BSA, 0.25 mM carnitine and 2µCi/ml [9,10-3H]-palmitic acid
793 (NET53100, PerkinElmer, Zaventem, Belgium). Tissues were incubated for 3 h in culture
794 medium at 37 C and 5 % CO₂, after which the supernatant was taken, and 10% Trichloroacetic
795 acid (TCA) added and incubated at room temperature for 15 min. Samples were spun down
796 at max speed for 10 min before 5% TCA was added followed by 10% BSA in TE buffer. After
797 15 min of incubation samples were spun down again and the supernatant was incubated with
798 Chloroform:Methanol (2:1) and KCl:HCl was added. Samples were spun down on last time,
799 before the supernatant was transferred into scintillation vials and 3H labeling was determined
800 using a b-counter. CPM values were background subtracted and normalized to mg wet weight
801 of the tissue.

802 **Isolation of Endothelial Cells**

803 Primary ECs from skeletal muscle (mECs) were isolated from adult WT and EC^{CD36^{-/-}}
804 littermates. Mice were euthanized, all hind-limb muscles were immediately dissected, and
805 muscles were minced in a Petri dish on ice using a surgical blade. Next, the minced muscle
806 tissue was enzymatically digested in digestion buffer containing 2 mg/mL Dispase II (D4693,
807 Sigma-Aldrich), 2 mg/mL Collagenase IV (17104019, Thermo Fisher Scientific) and 2 mM
808 CaCl₂ in PBS at 37°C for 40 min, with gentle shaking every 10 min. The reaction was stopped
809 by adding an equal volume of 20% FBS in HBSS and the suspension was passed through a
810 series of 100-µm cell strainers (Corning) and 70-µm cell strainers (Corning) to remove tissue
811 debris. After a series of centrifugation and washing steps, the heterogeneous cell population
812 was purified by FACS.

813 **Flow Cytometry**

814 Cells were incubated in PBS with the fixable viability dye eFluor® 780 (65-0865-14,
815 eBioscience) before antibody staining. Prior to surface staining with antibodies, Fc gamma
816 receptors were blocked by incubating cells with anti-CD16/CD32 antibodies (2.4G2,
817 homemade). Thereafter, cells were incubated with the appropriate primary antibodies (CD45,
818 CD31, CD36) diluted in FACS buffer (DPBS + 2% FCS) and subsequently incubated with
819 antibodies for 30 min on ice. For EdU proliferation experiments, cells from EdU-injected mice
820 were first stained with antibodies for cell surface markers and subsequently labeled with the
821 click-iT plus EdU Alexa Fluor® 488 Flow Cytometry Assay Kit (Life Technologies) according
822 to the manufacturer's instructions. Cells were analyzed with a LSRFortessa (BD Bioscience)
823 flow cytometer or sorted using a FACS Aria III (BD Bioscience) sorter. Data were analyzed
824 using FlowJo 10 software (Tree Star). A complete list of all antibodies and staining reagents
825 used can be found in Key Resources Table. The gating strategies used for flow cytometry
826 plots are shown in Figure S3.

827 **Enzyme-Linked Immunosorbent Assay (ELISA)**


828 Skeletal muscle tissue samples (10-15 mg) were homogenized with a tissue homogenizer
829 (Omni THq) in ice-cold lysis buffer (1:15 w/v) as described above. Homogenates were
830 centrifuged at 10000 g for 10 min at 4C, and VEGF was measured in the supernatants using
831 the Mouse VEGF Quantikine ELISA Kit (R&D System, MMV00) according to the
832 manufacturer's protocol.

833 **QUANTIFICATION AND STATISTICAL ANALYSIS**

834 The images presented in the manuscript are representative of the data (quantification of image
835 is approximately the group average) and the image/staining quality. All data represent mean
836 \pm SD. GraphPad Prism software (version 8.0.0) was used for statistical analyses.
837 Investigators were always blinded to group allocation. When comparing two group means,
838 Student's t test was used in an unpaired two-tailed fashion. For more than two groups, one-
839 way ANOVA with Tukey's multiple comparisons test was used and for experimental set-ups
840 with a second variable, two-way ANOVA with Sidak's multiple comparisons test was used.
841 The statistical method used for each experiment is indicated in each figure legend. No
842 experiment-wide multiple test correction was applied. $p > 0.05$ is considered non-significant.
843 $p < 0.05$ is considered significant.

844


845 **Supplemental Figures**



846 **Supplemental Figure 1 Short-term SAAR induces shifts in metabolism and increases**
 847 **endurance exercise capacity in young, sedentary male mice**

- 848 A. Percent change in body weight (n = 6) of male mice given *ad libitum* access to sulfur
849 amino acid restricted (SAAR) versus control (Con) diet for seven days.
- 850 B. Percent fat mass of total body weight measured using ECHO MRI (n = 6) of male mice
851 given *ad libitum* access to SAAR versus Con diet on day seven.
- 852 C. Percent lean mass of total body weight measured using ECHO MRI (n = 6) of male
853 mice given *ad libitum* access to SAAR versus Con diet on day seven.
- 854 D. Fat:lean mass ratio calculated from A and B (n = 6) of male mice given *ad libitum*
855 access to SAAR versus Con diet on day seven.
- 856 E. Percent change in body weight (n = 8) of female mice given *ad libitum* access to SAAR
857 versus Con diet after seven days on the diet.
- 858 F. Distance ran during a one-time maximal endurance test (n = 8) of female mice given
859 *ad libitum* access to SAAR versus Con diet.
- 860 G. Sable systems indirect calorimetry measurements of energy expenditure (kcal, EE)
861 over a 24 h period (n = 10) of mice given *ad libitum* access to SAAR versus Con diet
862 for seven days and
- 863 H. the average EE during a 12 h–12 h light–dark cycle (n = 10) of male mice given *ad*
864 *libitum* access to SAAR versus Con diet on day seven.
- 865 I. Sable systems indirect calorimetry measurements of sum of beam breaks
866 (counts/cycle, Locomotion) over a 24 h period (n = 10) of male mice given *ad libitum*
867 access to SAAR versus Con diet for seven days.
- 868 J. Sable systems indirect calorimetry measurements of voluntary wheel running behavior
869 over a 24 h period (n = 10) of male mice given *ad libitum* access to SAAR versus Con
870 diet for seven days.
- 871 K. Linear regression showing the relationship between relative change in body weight
872 versus distance ran (n = 16) of male mice given *ad libitum* access to SAAR versus Con
873 diet on day seven. R² coefficient was calculated using Pearson’s method.
- 874 L. Linear regression showing the relationship between absolute body weight versus
875 distance ran (n = 16) of male mice given *ad libitum* access to SAAR versus Con diet
876 on day seven. R² coefficient was calculated using Pearson’s method.
- 877 M. RER trajectory over time in seconds during a one-time maximal endurance test on
878 metabolic treadmills (Harvard Apparatus) (n = 10) of male mice given *ad libitum* access
879 to SAAR versus Con diet on day seven.
- 880 N. Time ran in seconds during a one-time maximal endurance test measured on
881 metabolic treadmills (n = 10) of male mice given *ad libitum* access to SAAR versus
882 Con diet.

883
884 All data is shown as mean and error bars indicate SD unless otherwise noted; p values indicate
885 the significance of the difference by Student’s t test or two-way ANOVA with Sidak’s multiple
886 comparisons test between diets or diet and cycle (indirect calorimetry); significance is
887 determined by a p value of p < 0.05. For linear regressions r squared Pearson’s coefficient
888 was calculated.



889

890

891


Supplemental Figure 2 Transcriptomics across muscle depots reveal metabolic shift from glycolytic toward oxidative

- 892 A. Pathway enrichment analysis comparing main effects of diet from bulkRNA
893 sequencing (n = 6) of male mice given *ad libitum* access to sulfur amino acid restricted
894 (SAAR) versus control (Con) diet on day seven showing all significantly increased or
895 decreased pathways.
- 896 B. Normalized count values of Myh7 in EDL and soleus from bulkRNA sequencing (n =
897 6) of male mice given *ad libitum* access to SAAR versus Con diet on day seven.
- 898 C. Normalized count values of Cd36 in EDL and soleus from bulkRNA sequencing (n =
899 6) of male mice given *ad libitum* access to SAAR versus Con diet on day seven.
- 900 D. Quantification of relative protein abundance normalized to vinculin of all five complexes
901 of the electron transport chain from blots shown in figure 2E of both EDL and
902 E. soleus (n = 5).
- 903 F. Fold changes of transcripts associated with known dietary SAAR and integrated stress
904 response (ISR) target genes (Torrence et al., 2021) after SAAR when compared to
905 Con.
- 906 G. Fold changes after Training (Furrer et al., 2023) and SAAR when compared to Con of
907 specific genes associated with mitochondrial matrix.
- 908 H. Fold changes after Training (Furrer et al., 2023) and SAAR when compared to Con of
909 specific genes associated with TCA cycle as identified in figure 2E.

910 All data is shown as mean and error bars indicate SD unless otherwise noted; p values indicate
911 the significance of the difference by Student's t test or two-way ANOVA with Sidak's multiple
912 comparisons test between diets or diet and complexes; significance is determined by a p value
913 of $p < 0.05$.

914

915



916

917

918


Supplemental Figure 3 SAAR increases muscle lipid flux without altering lipid pool sizes

- 919 A. Heatmap of differentially abundant free fatty acid species in muscles (n= 3-4) of male
920 mice given *ad libitum* access to sulfur amino acid restricted (SAAR) versus control
921 (Con) diet for seven days.
- 922 B. Representative histograms of CD36⁺ endothelial cells (EC) in the muscle and
923 C. gating strategy for CD36 positive EC (CD45⁻, CD31⁺, CD36⁺) isolated from muscle of
924 male WT (Cre⁻) and EC^{CD36^{-/-}} (Cre⁺) mice.
- 925 D. EC^{CD36^{-/-}} KO efficiency was confirmed by FACS analysis of CD31⁺/CD36⁺ MFI in
926 muscle or
927 E. brown adipose tissue (BAT) (n = 4) of male WT or EC^{CD36^{-/-}} mice.
- 928 F. Daily body weight trajectories shown in percent of starting body weight (n = 8/group)
929 over time of male WT and EC^{CD36^{-/-}} mice given *ad libitum* access to SAAR versus Con
930 diet for seven days.
- 931 G. Heatmap of differentially abundant free fatty acid species in muscles of male WT or
932 EC^{CD36^{-/-}} mice (n = 5) fed a Con or SAAR diet for seven days.
- 933 H. Heatmap of differentially abundant free fatty acid species in serum of male WT or
934 EC^{CD36^{-/-}} mice (n = 5) fed a Con or SAAR diet for seven days.

935

936 All data is shown as mean and error bars indicate SD unless otherwise noted; p values indicate
937 the significance of the difference by Student's t test between diets, or two-way ANOVA with
938 Sidak's multiple comparisons test between diets and muscle or genotype; significance is
939 determined by a p value of p < 0.05.

940




941
942
943

Supplemental Figure 4 FGF21 is dispensable for running phenotype after SAAR in male mice

- 944 A. Daily body weight trajectories shown in percent of starting body weight (n = 4-10) over
945 time, of male WT or FGF21KO mice given *ad libitum* access to sulfur amino acid
946 restricted (SAAR) versus control (Con) diet for seven days.
947 B. Food intake expressed as grams of food eaten per gram of mouse body weight within
948 a 24 hr period (n = 4-10) of male WT or FGF21KO mice given *ad libitum* access to
949 SAAR versus Con diet for seven days.
950 C. Serum FGF21 concentrations of male WT or FGF21 KO mice given *ad libitum* access
951 to SAAR versus Con diet for seven days determined using an ELISA.
952 D. Daily body weight trajectories over time shown in percent when compared to starting
953 body weight (n = 8) of NaCl or recombinant FGF21 treated male mice for seven days.
954 E. Fgf21 and Ucp1 mRNA levels in brown adipose tissue (BAT) of male mice given *ad*
955 *libitum* access to SAAR versus Con diet or mice treated with recombinant FGF21 for
956 seven days

957 All data is shown as mean and error bars indicate SD unless otherwise noted; p values indicate
958 the significance of the difference by Student's t test between diets, or two-way ANOVA with
959 Sidak's multiple comparisons test between diets and genotype; significance is determined by
960 a p value of $p < 0.05$.

961



962

963

964

Supplemental Figure 5 Inhibition of VEGFR signaling prevents endurance exercise phenotype without induction of angiogenesis

- 965 A. Normalized count values of Vegfa in EDL and soleus from bulkRNA sequencing (n =
966 6) of male mice given *ad libitum* access to sulfur amino acid restricted (SAAR) versus
967 control (Con) diet on day seven.
- 968 B. Normalized count values of Kdr in EDL and soleus from bulkRNA sequencing (n = 6)
969 of male mice given *ad libitum* access to SAAR versus Con diet on day seven.
- 970 C. Daily body weight trajectories shown in percent of starting body weight (n = 10) over
971 time of male mice given *ad libitum* access to SAAR versus Con diet for seven days,
972 treated with either vehicle (veh) or axitinib by oral gavage.
- 973 D. Quantification of IB4⁺ area of EDL muscle of male mice fed a Con or SAAR for seven
974 days treated with veh or axitinib (n = 5-8).
- 975 E. Cell counts of EdU⁺/CD31⁺ double positive cells per mg tissue in muscle from male
976 mice given *ad libitum* access to SAAR versus Con diet for seven days and injected
977 with EdU to label cell proliferation, determined by flow cytometry.
- 978 F. Cell counts of CD31⁺ positive cells per mg tissue in muscle or
979 G. brown adipose tissue (BAT) or of male mice given *ad libitum* access to SAAR versus
980 Con diet for seven days, determined by flow cytometry.
- 981 H. Normalized count values of Vegfa in EDL treated with veh or axitinib from bulkRNA
982 sequencing (n = 5) of male mice given *ad libitum* access to SAAR versus Con diet on
983 day seven.
- 984 I. Normalized count values of Kdr in EDL treated with veh or axitinib from bulkRNA
985 sequencing (n = 5) of male mice given *ad libitum* access to SAAR versus Con diet on
986 day seven.
- 987 J. Fold changes of transcripts associated with fatty acid (FA) catabolism and transport as
988 identified in supplementary figure 2A in both EDL treated with veh or axitinib after
989 bulkRNA sequencing (n = 5) of male mice given *ad libitum* access to SAAR versus
990 Con diet on day seven.
- 991 K. Fold changes of transcripts associated with electron transport chain (ETC) associated
992 genes in EDL treated with veh or axitinib after bulkRNA sequencing (n = 6) of male
993 mice given *ad libitum* access to SAAR versus Con diet on day seven.
- 994 L. Body weight trajectory over time, shown as percent of starting body weight (n = 8-10)
995 of male mice given *ad libitum* access to SAAR versus Con diet for seven days treated
996 with IgG or DC101 via i.p. injection every other day.
- 997 M. Food intake expressed as grams of food per gram of body weight per mouse within a
998 24 hr period (n = 8-10) of male mice given *ad libitum* access to SAAR versus Con diet
999 treated with IgG or DC101 via i.p. injection every other day on day seven.

1000 All data is shown as mean and error bars indicate SD unless otherwise noted; p values indicate
1001 the significance of the difference by Student's t test between diets, or two-way ANOVA with
1002 Sidak's multiple comparisons test between diets and muscle or treatment; significance is
1003 determined by a p value of $p < 0.05$.

1004 References

- 1005 Abcouwer, S.F., Marjon, P.L., Loper, R.K., Vander Jagt, D.L., 2002. Response of VEGF
1006 expression to amino acid deprivation and inducers of endoplasmic reticulum stress.
1007 *Invest. Ophthalmol. Vis. Sci.* 43, 2791–2798.
- 1008 Agius, T., Emsley, R., Lyon, A., MacArthur, M.R., Kiesworo, K., Faivre, A., Stavart, L.,
1009 Lambelet, M., Legouis, D., De Seigneux, S., Golshayan, D., Lazeyras, F., Yeh, H.,
1010 Markmann, J.F., Uygun, K., Ocampo, A., Mitchell, S.J., Allagnat, F., Déglise, S.,
1011 Longchamp, A., 2024. Short-term hypercaloric carbohydrate loading increases
1012 surgical stress resilience by inducing FGF21. *Nat. Commun.* 15, 1073.
1013 <https://doi.org/10.1038/s41467-024-44866-3>
- 1014 Arany, Z., Foo, S.-Y., Ma, Y., Ruas, J.L., Bommi-Reddy, A., Girnun, G., Cooper, M., Laznik,
1015 D., Chinsomboon, J., Rangwala, S.M., Baek, K.H., Rosenzweig, A., Spiegelman,
1016 B.M., 2008. HIF-independent regulation of VEGF and angiogenesis by the
1017 transcriptional coactivator PGC-1 α . *Nature* 451, 1008–1012.
1018 <https://doi.org/10.1038/nature06613>
- 1019 Bloor, C.M., 2005. Angiogenesis during exercise and training. *Angiogenesis* 8, 263–271.
1020 <https://doi.org/10.1007/s10456-005-9013-x>
- 1021 Brooke, M.H., Kaiser, K.K., 1970. Muscle Fiber Types: How Many and What Kind? *Arch.*
1022 *Neurol.* 23, 369–379. <https://doi.org/10.1001/archneur.1970.00480280083010>
- 1023 Brown, M.D., 1973. Role of Activity in the Differentiation of Slow and Fast Muscles. *Nature*
1024 244, 178–179. <https://doi.org/10.1038/244178a0>
- 1025 Claxton, S., Kostourou, V., Jadeja, S., Chambon, P., Hodivala-Dilke, K., Fruttiger, M., 2008.
1026 Efficient, inducible Cre-recombinase activation in vascular endothelium. *genesis* 46,
1027 74–80. <https://doi.org/10.1002/dvg.20367>
- 1028 Das, A., Huang, G.X., Bonkowski, M.S., Longchamp, A., Li, C., Schultz, M.B., Kim, L.-J.,
1029 Osborne, B., Joshi, S., Lu, Y., Treviño-Villarreal, J.H., Kang, M.-J., Hung, T., Lee, B.,
1030 Williams, E.O., Igarashi, M., Mitchell, J.R., Wu, L.E., Turner, N., Arany, Z., Guarente,
1031 L., Sinclair, D.A., 2018. Impairment of an Endothelial NAD⁺-H₂S Signaling Network
1032 Is a Reversible Cause of Vascular Aging. *Cell* 173, 74-89.e20.
1033 <https://doi.org/10.1016/j.cell.2018.02.008>
- 1034 De Bock, K., Georgiadou, M., Schoors, S., Kuchnio, A., Wong, B.W., Cantelmo, A.R.,
1035 Quaegebeur, A., Ghesquière, B., Cauwenberghs, S., Eelen, G., Phng, L.-K., Betz, I.,
1036 Tembuysen, B., Brepoels, K., Welti, J., Geudens, I., Segura, I., Cruys, B., Bifari, F.,
1037 Decimo, I., Blanco, R., Wyns, S., Vangindertael, J., Rocha, S., Collins, R.T., Munck,
1038 S., Daelemans, D., Imamura, H., Devlieger, R., Rider, M., Van Veldhoven, P.P.,
1039 Schuit, F., Bartrons, R., Hofkens, J., Fraisl, P., Telang, S., DeBerardinis, R.J.,
1040 Schoonjans, L., Vinckier, S., Chesney, J., Gerhardt, H., Dewerchin, M., Carmeliet, P.,
1041 2013. Role of PFKFB3-Driven Glycolysis in Vessel Sprouting. *Cell* 154, 651–663.
1042 <https://doi.org/10.1016/j.cell.2013.06.037>
- 1043 Delavar, H., Nogueira, L., Wagner, P.D., Hogan, M.C., Metzger, D., Breen, E.C., 2014.
1044 Skeletal myofiber VEGF is essential for the exercise training response in adult mice.
1045 *Am. J. Physiol.-Regul. Integr. Comp. Physiol.* 306, R586–R595.
1046 <https://doi.org/10.1152/ajpregu.00522.2013>
- 1047 Dijkstra, M.H., Pirinen, E., Huusko, J., Kivelä, R., Schenkwein, D., Alitalo, K., Ylä-Herttua,
1048 S., 2014. Lack of cardiac and high-fat diet induced metabolic phenotypes in two
1049 independent strains of Vegf-b knockout mice. *Sci. Rep.* 4, 6238.
1050 <https://doi.org/10.1038/srep06238>
- 1051 Egan, B., Zierath, J.R., 2013. Exercise Metabolism and the Molecular Regulation of Skeletal
1052 Muscle Adaptation. *Cell Metab.* 17, 162–184.
1053 <https://doi.org/10.1016/j.cmet.2012.12.012>
- 1054 Falkevall, A., Mehlem, A., Palombo, I., Heller Sahlgren, B., Ebarasi, L., He, L., Ytterberg,
1055 A.J., Olauson, H., Axelsson, J., Sundelin, B., Patrakka, J., Scotney, P., Nash, A.,
1056 Eriksson, U., 2017. Reducing VEGF-B Signaling Ameliorates Renal Lipotoxicity and

- 1057 Protects against Diabetic Kidney Disease. *Cell Metab.* 25, 713–726.
1058 <https://doi.org/10.1016/j.cmet.2017.01.004>
- 1059 Fan, Z., Turiel, G., Ardicoglu, R., Ghobrial, M., Masschelein, E., Kocijan, T., Zhang, J., Tan,
1060 G., Fitzgerald, G., Gorski, T., Alvarado-Diaz, A., Gilardoni, P., Adams, C.M.,
1061 Ghesquière, B., De Bock, K., 2021. Exercise-induced angiogenesis is dependent on
1062 metabolically primed ATF3/4+ endothelial cells. *Cell Metab.* 33, 1793-1807.e9.
1063 <https://doi.org/10.1016/j.cmet.2021.07.015>
- 1064 Fontana, L., Partridge, L., 2015. Promoting Health and Longevity through Diet: From Model
1065 Organisms to Humans. *Cell* 161, 106–118. <https://doi.org/10.1016/j.cell.2015.02.020>
- 1066 Forney, L.A., Fang, H., Sims, L.C., Stone, K.P., Vincik, L.Y., Vick, A.M., Gibson, A.N., Burk,
1067 D.H., Gettys, T.W., 2020. Dietary Methionine Restriction Signals to the Brain Through
1068 Fibroblast Growth Factor 21 to Regulate Energy Balance and Remodeling of Adipose
1069 Tissue. *Obesity* 28, 1912–1921. <https://doi.org/10.1002/oby.22919>
- 1070 Furrer, R., Heim, B., Schmid, S., Dilbaz, S., Adak, V., Nordström, K.J.V., Ritz, D., Steurer,
1071 S.A., Walter, J., Handschin, C., 2023. Molecular control of endurance training
1072 adaptation in male mouse skeletal muscle. *Nat. Metab.* 5, 2020–2035.
1073 <https://doi.org/10.1038/s42255-023-00891-y>
- 1074 Ghosh, S., Forney, L.A., Wanders, D., Stone, K.P., Gettys, T.W., 2017. An integrative
1075 analysis of tissue-specific transcriptomic and metabolomic responses to short-term
1076 dietary methionine restriction in mice. *PLOS ONE* 12, e0177513.
1077 <https://doi.org/10.1371/journal.pone.0177513>
- 1078 Ghosh, S., Wanders, D., Stone, K.P., Van, N.T., Cortez, C.C., Gettys, T.W., 2014. A
1079 systems biology analysis of the unique and overlapping transcriptional responses to
1080 caloric restriction and dietary methionine restriction in rats. *FASEB J.* 28, 2577–2590.
1081 <https://doi.org/10.1096/fj.14-249458>
- 1082 Gorski, T., Bock, K.D., 2019. Metabolic regulation of exercise-induced angiogenesis. *Vasc.*
1083 *Biol.* 1, H1–H8. <https://doi.org/10.1530/VB-19-0008>
- 1084 Grobe, J.L., 2017. Comprehensive Assessments of Energy Balance in Mice, in: Thatcher,
1085 S.E. (Ed.), *The Renin-Angiotensin-Aldosterone System: Methods and Protocols*.
1086 Springer, New York, NY, pp. 123–146. https://doi.org/10.1007/978-1-4939-7030-8_10
- 1087 Gu, Z., 2022. Complex heatmap visualization. *iMeta* 1, e43. <https://doi.org/10.1002/imt2.43>
- 1088 Haas, T.L., Nwadozi, E., 2015. Regulation of skeletal muscle capillary growth in exercise
1089 and disease. *Appl. Physiol. Nutr. Metab.* 40, 1221–1232.
1090 <https://doi.org/10.1139/apnm-2015-0336>
- 1091 Hagberg, C.E., Falkevall, A., Wang, X., Larsson, E., Huusko, J., Nilsson, I., Van Meeteren,
1092 L.A., Samen, E., Lu, L., Vanwildemeersch, M., Klar, J., Genove, G., Pietras, K.,
1093 Stone-Elander, S., Claesson-Welsh, L., Ylä-Herttuala, S., Lindahl, P., Eriksson, U.,
1094 2010. Vascular endothelial growth factor B controls endothelial fatty acid uptake.
1095 *Nature* 464, 917–921. <https://doi.org/10.1038/nature08945>
- 1096 Han, Y., Hu, Z., Cui, A., Liu, Z., Ma, F., Xue, Y., Liu, Y., Zhang, F., Zhao, Z., Yu, Y., Gao, J.,
1097 Wei, C., Li, Jingya, Fang, J., Li, Jia, Fan, J.-G., Song, B.-L., Li, Y., 2019. Post-
1098 translational regulation of lipogenesis via AMPK-dependent phosphorylation of
1099 insulin-induced gene. *Nat. Commun.* 10, 623. <https://doi.org/10.1038/s41467-019-08585-4>
- 1100
- 1101 Hasek, B.E., Stewart, L.K., Henagan, T.M., Boudreau, A., Lenard, N.R., Black, C., Shin, J.,
1102 Huypens, P., Malloy, V.L., Plaisance, E.P., Krajcik, R.A., Orentreich, N., Gettys,
1103 T.W., 2010. Dietary methionine restriction enhances metabolic flexibility and
1104 increases uncoupled respiration in both fed and fasted states. *Am. J. Physiol.-Regul.*
1105 *Integr. Comp. Physiol.* 299, R728–R739. <https://doi.org/10.1152/ajpregu.00837.2009>
- 1106 Hill, C.M., Laeger, T., Dehner, M., Albarado, D.C., Clarke, B., Wanders, D., Burke, S.J.,
1107 Collier, J.J., Qualls-Creekmore, E., Solon-Biet, S.M., Simpson, S.J., Berthoud, H.-R.,
1108 Münzberg, H., Morrison, C.D., 2019. FGF21 Signals Protein Status to the Brain and
1109 Adaptively Regulates Food Choice and Metabolism. *Cell Rep.* 27, 2934-2947.e3.
1110 <https://doi.org/10.1016/j.celrep.2019.05.022>
- 1110

- 1111 Hine, C., Harputlugil, E., Zhang, Y., Ruckenstuhl, C., Lee, B.C., Brace, L., Longchamp, A.,
1112 Treviño-Villarreal, J.H., Mejia, P., Ozaki, C.K., Wang, R., Gladyshev, V.N., Madeo,
1113 F., Mair, W.B., Mitchell, J.R., 2015. Endogenous Hydrogen Sulfide Production Is
1114 Essential for Dietary Restriction Benefits. *Cell* 160, 132–144.
1115 <https://doi.org/10.1016/j.cell.2014.11.048>
- 1116 Hui, S., Cowan, A.J., Zeng, X., Yang, L., TeSlaa, T., Li, X., Bartman, C., Zhang, Z., Jang, C.,
1117 Wang, L., Lu, W., Rojas, J., Baur, J., Rabinowitz, J.D., 2020. Quantitative Fluxomics
1118 of Circulating Metabolites. *Cell Metab.* 32, 676–688.e4.
1119 <https://doi.org/10.1016/j.cmet.2020.07.013>
- 1120 Iso, T., Haruyama, H., Sunaga, H., Matsui, H., Matsui, M., Tanaka, R., Umbarawan, Y.,
1121 Syamsunarno, M.R.A.A., Putri, M., Yamaguchi, A., Hanaoka, H., Negishi, K.,
1122 Yokoyama, T., Kurabayashi, M., 2018. CD36 is indispensable for nutrient
1123 homeostasis and endurance exercise capacity during prolonged fasting. *Physiol.*
1124 *Rep.* 6, e13884. <https://doi.org/10.14814/phy2.13884>
- 1125 Jonsson, W.O., Margolies, N.S., Mirek, E.T., Zhang, Q., Linden, M.A., Hill, C.M., Link, C.,
1126 Bithi, N., Zalma, B., Levy, J.L., Pettit, A.P., Miller, J.W., Hine, C., Morrison, C.D.,
1127 Gettys, T.W., Miller, B.F., Hamilton, K.L., Wek, R.C., Anthony, T.G., 2021.
1128 Physiologic Responses to Dietary Sulfur Amino Acid Restriction in Mice Are
1129 Influenced by Atf4 Status and Biological Sex. *J. Nutr.* 151, 785–799.
1130 <https://doi.org/10.1093/jn/nxaa396>
- 1131 Kivelä, R., Hemanthakumar, K.A., Vaparanta, K., Robciuc, M., Izumiya, Y., Kidoya, H.,
1132 Takakura, N., Peng, X., Sawyer, D.B., Elenius, K., Walsh, K., Alitalo, K., 2019.
1133 Endothelial Cells Regulate Physiological Cardiomyocyte Growth via VEGFR2-
1134 Mediated Paracrine Signaling. *Circulation* 139, 2570–2584.
1135 <https://doi.org/10.1161/CIRCULATIONAHA.118.036099>
- 1136 Kondo, M., Shibata, R., Miura, R., Shimano, M., Kondo, K., Li, P., Ohashi, T., Kihara, S.,
1137 Maeda, N., Walsh, K., Ouchi, N., Murohara, T., 2009. Caloric Restriction Stimulates
1138 Revascularization in Response to Ischemia via Adiponectin-mediated Activation of
1139 Endothelial Nitric-oxide Synthase*. *J. Biol. Chem.* 284, 1718–1724.
1140 <https://doi.org/10.1074/jbc.M805301200>
- 1141 Lee, M.B., Hill, C.M., Bitto, A., Kaerberlein, M., 2021. Antiaging diets: Separating fact from
1142 fiction. *Science* 374, eabe7365. <https://doi.org/10.1126/science.abe7365>
- 1143 Lees, E.K., Król, E., Grant, L., Shearer, K., Wyse, C., Moncur, E., Bykowska, A.S., Mody, N.,
1144 Gettys, T.W., Delibegovic, M., 2014. Methionine restriction restores a younger
1145 metabolic phenotype in adult mice with alterations in fibroblast growth factor 21.
1146 *Aging Cell* 13, 817–827. <https://doi.org/10.1111/accel.12238>
- 1147 Li, K., Wang, M., Wang, R., Wang, X., Jiao, H., Zhao, J., Zhou, Y., Li, H., Lin, H., 2023.
1148 Hydrogen Sulfide Regulates Glucose Uptake in Skeletal Muscles via S-Sulfhydration
1149 of AMPK in Muscle Fiber Type-Dependent Way. *J. Nutr.* 153, 2878–2892.
1150 <https://doi.org/10.1016/j.tjnut.2023.08.024>
- 1151 Li, X., Hui, S., Mirek, E.T., Jonsson, W.O., Anthony, T.G., Lee, W.D., Zeng, X., Jang, C.,
1152 Rabinowitz, J.D., 2022. Circulating metabolite homeostasis achieved through mass
1153 action. *Nat. Metab.* 4, 141–152. <https://doi.org/10.1038/s42255-021-00517-1>
- 1154 Liao, Y., Smyth, G.K., Shi, W., 2019. The R package Rsubread is easier, faster, cheaper and
1155 better for alignment and quantification of RNA sequencing reads. *Nucleic Acids Res.*
1156 47, e47. <https://doi.org/10.1093/nar/gkz114>
- 1157 Longchamp, A., Mirabella, T., Arduini, A., MacArthur, M.R., Das, A., Treviño-Villarreal, J.H.,
1158 Hine, C., Ben-Sahra, I., Knudsen, N.H., Brace, L.E., Reynolds, J., Mejia, P., Tao, M.,
1159 Sharma, G., Wang, R., Corpataux, J.-M., Haefliger, J.-A., Ahn, K.H., Lee, C.-H.,
1160 Manning, B.D., Sinclair, D.A., Chen, C.S., Ozaki, C.K., Mitchell, J.R., 2018. Amino
1161 Acid Restriction Triggers Angiogenesis via GCN2/ATF4 Regulation of VEGF and
1162 H₂S Production. *Cell* 173, 117–129.e14. <https://doi.org/10.1016/j.cell.2018.03.001>
- 1163 Love, M.I., Huber, W., Anders, S., 2014. Moderated estimation of fold change and dispersion
1164 for RNA-seq data with DESeq2. *Genome Biol.* 15, 550.
1165 <https://doi.org/10.1186/s13059-014-0550-8>

- 1166 Luo, L., Ma, W., Liang, K., Wang, Y., Su, J., Liu, R., Liu, T., Shyh-Chang, N., 2023. Spatial
1167 metabolomics reveals skeletal myofiber subtypes. *Sci. Adv.* 9, eadd0455.
1168 <https://doi.org/10.1126/sciadv.add0455>
- 1169 MacArthur, M.R., Mitchell, S.J., Chadaideh, K.S., Treviño-Villarreal, J.H., Jung, J., Kalafut,
1170 K.C., Reynolds, J.S., Mann, C.G., Trocha, K.M., Tao, M., Aye Cho, T.-Z.,
1171 Koontanatechanon, A., Yeliseyev, V., Bry, L., Longchamp, A., Ozaki, C.K., Lewis,
1172 C.A., Carmody, R.N., Mitchell, J.R., 2022. Multiomics assessment of dietary protein
1173 titration reveals altered hepatic glucose utilization. *Cell Rep.* 40, 111187.
1174 <https://doi.org/10.1016/j.celrep.2022.111187>
- 1175 Matsakas, A., Yadav, V., Lorca, S., Evans, R.M., Narkar, V.A., 2012. Revascularization of
1176 Ischemic Skeletal Muscle by Estrogen-Related Receptor- γ . *Circ. Res.* 110, 1087–
1177 1096. <https://doi.org/10.1161/CIRCRESAHA.112.266478>
- 1178 McCay, C.M., Crowell, M.F., Maynard, L.A., 1935. The Effect of Retarded Growth Upon the
1179 Length of Life Span and Upon the Ultimate Body Size. *J. Nutr.* 10, 63–79.
1180 <https://doi.org/10.1093/jn/10.1.63>
- 1181 Mehlem, A., Palombo, I., Wang, X., Hagberg, C.E., Eriksson, U., Falkevall, A., 2016. PGC-
1182 1 α Coordinates Mitochondrial Respiratory Capacity and Muscular Fatty Acid Uptake
1183 via Regulation of VEGF-B. *Diabetes* 65, 861–873. <https://doi.org/10.2337/db15-1231>
- 1184 Miller, R.A., Buehner, G., Chang, Y., Harper, J.M., Sigler, R., Smith-Wheelock, M., 2005.
1185 Methionine-deficient diet extends mouse lifespan, slows immune and lens aging,
1186 alters glucose, T4, IGF-I and insulin levels, and increases hepatocyte MIF levels and
1187 stress resistance. *Aging Cell* 4, 119–125. <https://doi.org/10.1111/j.1474-9726.2005.00152.x>
- 1189 Nagata, D., Mogi, M., Walsh, K., 2003. AMP-activated Protein Kinase (AMPK) Signaling in
1190 Endothelial Cells Is Essential for Angiogenesis in Response to Hypoxic Stress*. *J.*
1191 *Biol. Chem.* 278, 31000–31006. <https://doi.org/10.1074/jbc.M300643200>
- 1192 Narkar, V.A., Fan, W., Downes, M., Yu, R.T., Jonker, J.W., Alaynick, W.A., Banayo, E.,
1193 Karunasiri, M.S., Lorca, S., Evans, R.M., 2011. Exercise and PGC-1 α -Independent
1194 Synchronization of Type I Muscle Metabolism and Vasculature by ERR γ . *Cell Metab.*
1195 13, 283–293. <https://doi.org/10.1016/j.cmet.2011.01.019>
- 1196 Ning, F.C., Jensen, N., Mi, J., Lindström, W., Balan, M., Muhl, L., Eriksson, U., Nilsson, I.,
1197 Nyqvist, D., 2020. VEGF-B ablation in pancreatic β -cells upregulates insulin
1198 expression without affecting glucose homeostasis or islet lipid uptake. *Sci. Rep.* 10,
1199 923. <https://doi.org/10.1038/s41598-020-57599-2>
- 1200 Olfert, I.M., Howlett, R.A., Tang, K., Dalton, N.D., Gu, Y., Peterson, K.L., Wagner, P.D.,
1201 Breen, E.C., 2009. Muscle-specific VEGF deficiency greatly reduces exercise
1202 endurance in mice. *J. Physiol.* 587, 1755–1767.
1203 <https://doi.org/10.1113/jphysiol.2008.164384>
- 1204 Olsson, A.-K., Dimberg, A., Kreuger, J., Claesson-Welsh, L., 2006. VEGF receptor
1205 signalling ? in control of vascular function. *Nat. Rev. Mol. Cell Biol.* 7, 359–371.
1206 <https://doi.org/10.1038/nrm1911>
- 1207 Omodei, D., Fontana, L., 2011. Calorie restriction and prevention of age-associated chronic
1208 disease. *FEBS Lett., Turin Special Issue: Biochemistry for Tomorrow's Medicine* 585,
1209 1537–1542. <https://doi.org/10.1016/j.febslet.2011.03.015>
- 1210 Orentreich, N., Matias, J.R., DeFelice, A., Zimmerman, J.A., 1993. Low Methionine Ingestion
1211 by Rats Extends Life Span. *J. Nutr.* 123, 269–274.
1212 <https://doi.org/10.1093/jn/123.2.269>
- 1213 Osborne, T.B., Mendel, L.B., Ferry, E.L., 1917. The Effect of Retardation of Growth Upon the
1214 Breeding Period and Duration of Life of Rats. *Science* 45, 294–295.
1215 <https://doi.org/10.1126/science.45.1160.294>
- 1216 Patil, Y.N., Dille, K.N., Burk, D.H., Cortez, C.C., Gettys, T.W., 2015. Cellular and molecular
1217 remodeling of inguinal adipose tissue mitochondria by dietary methionine restriction.
1218 *J. Nutr. Biochem.* 26, 1235–1247. <https://doi.org/10.1016/j.jnutbio.2015.05.016>
- 1219 Peche, V.S., Pietka, T.A., Jacome-Sosa, M., Samovski, D., Palacios, H., Chatterjee-Basu,
1220 G., Dudley, A.C., Beatty, W., Meyer, G.A., Goldberg, I.J., Abumrad, N.A., 2023.

- 1221 Endothelial cell CD36 regulates membrane ceramide formation, exosome fatty acid
1222 transfer and circulating fatty acid levels. *Nat. Commun.* 14, 4029.
1223 <https://doi.org/10.1038/s41467-023-39752-3>
- 1224 Perrone, C.E., Mattocks, D.A.L., Jarvis-Morar, M., Plummer, J.D., Orentreich, N., 2010.
1225 Methionine restriction effects on mitochondrial biogenesis and aerobic capacity in
1226 white adipose tissue, liver, and skeletal muscle of F344 rats. *Metabolism* 59, 1000–
1227 1011. <https://doi.org/10.1016/j.metabol.2009.10.023>
- 1228 Perrone, C.E., Mattocks, D.A.L., Plummer, J.D., Chittur, S.V., Mohney, R., Vignola, K.,
1229 Orentreich, D.S., Orentreich, N., 2012. Genomic and Metabolic Responses to
1230 Methionine-Restricted and Methionine-Restricted, Cysteine-Supplemented Diets in
1231 Fischer 344 Rat Inguinal Adipose Tissue, Liver and Quadriceps Muscle. *Lifestyle*
1232 *Genomics* 5, 132–157. <https://doi.org/10.1159/000339347>
- 1233 Potente, M., Gerhardt, H., Carmeliet, P., 2011. Basic and Therapeutic Aspects of
1234 Angiogenesis. *Cell* 146, 873–887. <https://doi.org/10.1016/j.cell.2011.08.039>
- 1235 Reihill, J.A., Ewart, M.-A., Salt, I.P., 2011. The role of AMP-activated protein kinase in the
1236 functional effects of vascular endothelial growth factor-A and -B in human aortic
1237 endothelial cells. *Vasc. Cell* 3, 9. <https://doi.org/10.1186/2045-824X-3-9>
- 1238 Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., Smyth, G.K., 2015. limma
1239 powers differential expression analyses for RNA-sequencing and microarray studies.
1240 *Nucleic Acids Res.* 43, e47. <https://doi.org/10.1093/nar/gkv007>
- 1241 Robciuc, M.R., Kivelä, R., Williams, I.M., de Boer, J.F., van Dijk, T.H., Elamaa, H., Tigistu-
1242 Sahle, F., Molotkov, D., Leppänen, V.-M., Käkelä, R., Eklund, L., Wasserman, D.H.,
1243 Groen, A.K., Alitalo, K., 2016. VEGFB/VEGFR1-Induced Expansion of Adipose
1244 Vasculature Counteracts Obesity and Related Metabolic Complications. *Cell Metab.*
1245 23, 712–724. <https://doi.org/10.1016/j.cmet.2016.03.004>
- 1246 Roberts, L.D., Boström, P., O’Sullivan, J.F., Schinzel, R.T., Lewis, G.D., Dejam, A., Lee, Y.-
1247 K., Palma, M.J., Calhoun, S., Georgiadi, A., Chen, M.-H., Ramachandran, V.S.,
1248 Larson, M.G., Bouchard, C., Rankinen, T., Souza, A.L., Clish, C.B., Wang, T.J.,
1249 Estall, J.L., Soukas, A.A., Cowan, C.A., Spiegelman, B.M., Gerszten, R.E., 2014. β -
1250 Aminoisobutyric Acid Induces Browning of White Fat and Hepatic β -Oxidation and Is
1251 Inversely Correlated with Cardiometabolic Risk Factors. *Cell Metab.* 19, 96–108.
1252 <https://doi.org/10.1016/j.cmet.2013.12.003>
- 1253 Rowe, G.C., Jang, C., Patten, I.S., Arany, Z., 2011. PGC-1 β regulates angiogenesis in
1254 skeletal muscle. *Am. J. Physiol.-Endocrinol. Metab.* 301, E155–E163.
1255 <https://doi.org/10.1152/ajpendo.00681.2010>
- 1256 Rowe, G.C., Safdar, A., Arany, Z., 2014. Running Forward: New Frontiers in Endurance
1257 Exercise Biology. *Circulation* 129, 798–810.
1258 <https://doi.org/10.1161/CIRCULATIONAHA.113.001590>
- 1259 Salminen, A., Kauppinen, A., Kaarniranta, K., 2017. FGF21 activates AMPK signaling:
1260 impact on metabolic regulation and the aging process. *J. Mol. Med.* 95, 123–131.
1261 <https://doi.org/10.1007/s00109-016-1477-1>
- 1262 Son, N.-H., Basu, D., Samovski, D., Pietka, T.A., Peche, V.S., Willecke, F., Fang, X., Yu, S.-
1263 Q., Scerbo, D., Chang, H.R., Sun, F., Bagdasarov, S., Drosatos, K., Yeh, S.T.,
1264 Mullick, A.E., Shoghi, K.I., Gumaste, N., Kim, K., Huggins, L.-A., Lhaxhang, T.,
1265 Abumrad, N.A., Goldberg, I.J., 2018. Endothelial cell CD36 optimizes tissue fatty acid
1266 uptake. *J. Clin. Invest.* 128, 4329–4342. <https://doi.org/10.1172/JCI99315>
- 1267 Speakman, J.R., 2013. Measuring Energy Metabolism in the Mouse – Theoretical, Practical,
1268 and Analytical Considerations. *Front. Physiol.* 4, 34.
1269 <https://doi.org/10.3389/fphys.2013.00034>
- 1270 Stahmann, N., Woods, A., Spengler, K., Heslegrave, A., Bauer, R., Krause, S., Viollet, B.,
1271 Carling, D., Heller, R., 2010. Activation of AMP-activated Protein Kinase by Vascular
1272 Endothelial Growth Factor Mediates Endothelial Angiogenesis Independently of
1273 Nitric-oxide Synthase*. *J. Biol. Chem.* 285, 10638–10652.
1274 <https://doi.org/10.1074/jbc.M110.108688>

- 1275 Swaminathan, A., Fokin, A., Venckūnas, T., Degens, H., 2021. Methionine restriction plus
1276 overload improves skeletal muscle and metabolic health in old mice on a high fat
1277 diet. *Sci. Rep.* 11, 1260. <https://doi.org/10.1038/s41598-021-81037-6>
- 1278 Torrence, M.E., MacArthur, M.R., Hosios, A.M., Valvezan, A.J., Asara, J.M., Mitchell, J.R.,
1279 Manning, B.D., 2021. The mTORC1-mediated activation of ATF4 promotes protein
1280 and glutathione synthesis downstream of growth signals. *eLife* 10, e63326.
1281 <https://doi.org/10.7554/eLife.63326>
- 1282 Wanders, D., Forney, L.A., Stone, K.P., Burk, D.H., Pierse, A., Gettys, T.W., 2017. FGF21
1283 Mediates the Thermogenic and Insulin-Sensitizing Effects of Dietary Methionine
1284 Restriction but Not Its Effects on Hepatic Lipid Metabolism. *Diabetes* 66, 858–867.
1285 <https://doi.org/10.2337/db16-1212>
- 1286 Wu, T., Hu, E., Xu, S., Chen, M., Guo, P., Dai, Z., Feng, T., Zhou, L., Tang, W., Zhan, L., Fu,
1287 X., Liu, S., Bo, X., Yu, G., 2021. clusterProfiler 4.0: A universal enrichment tool for
1288 interpreting omics data. *The Innovation* 2, 100141.
1289 <https://doi.org/10.1016/j.xinn.2021.100141>
- 1290 Yu, D., Yang, S.E., Miller, B.R., Wisinski, J.A., Sherman, D.S., Brinkman, J.A., Tomaszewicz,
1291 J.L., Cummings, N.E., Kimple, M.E., Cryns, V.L., Lamming, D.W., 2018. Short-term
1292 methionine deprivation improves metabolic health *via* sexually dimorphic, mTORCI-
1293 independent mechanisms. *FASEB J.* 32, 3471–3482.
1294 <https://doi.org/10.1096/fj.201701211R>
- 1295 Zivanovic, J., Kouroussis, E., Kohl, J.B., Adhikari, B., Bursac, B., Schott-Roux, S., Petrovic,
1296 D., Miljkovic, J.Lj., Thomas-Lopez, D., Jung, Y., Miler, M., Mitchell, S., Milosevic, V.,
1297 Gomes, J.E., Benhar, M., Gonzalez-Zorn, B., Ivanovic-Burmazovic, I., Torregrossa,
1298 R., Mitchell, J.R., Whiteman, M., Schwarz, G., Snyder, S.H., Paul, B.D., Carroll, K.S.,
1299 Filipovic, M.R., 2019. Selective Persulfide Detection Reveals Evolutionarily
1300 Conserved Antiaging Effects of S-Sulfhydration. *Cell Metab.* 30, 1152-1170.e13.
1301 <https://doi.org/10.1016/j.cmet.2019.10.007>
- 1302
- 1303

- 1304 **Supplemental Table 1 Raw data from metabolic treadmill measurements.**
- 1305 **Supplemental Table 2 Raw counts data from RNA sequencing analysis looking at**
1306 **muscle and diet interaction.**
- 1307 **Supplemental Table 3 Raw normalized ion counts from lipidomics analysis looking at**
1308 **muscle and diet interaction.**
- 1309 **Supplemental Table 4 Raw normalized ion counts from metabolomics analysis looking**
1310 **at muscle and diet interaction.**
- 1311 **Supplemental Table 5 Raw normalized ion counts from metabolomics analysis looking**
1312 **at muscle and diet interaction in different tissues from WT and CD36^{EC-/-} mice**
- 1313 **Supplemental Table 6 Raw counts data from RNA sequencing analysis looking at diet**
1314 **and axitinib treatment interaction in EDL muscle.**



A17101101-03

Formulated by
Research Diets, Inc
12/14/2022

Product #	A17101101	A17101102	A17101103
Ingredient	Control	Mid Methionine	Low Methionine
Casein, Lactic	0	0	0
L-Cystine	0	0	0
L-Isoleucine	7.6	7.6	7.6
L-Leucine	15.8	15.8	15.8
L-Lysine	13.2	13.2	13.2
L-Methionine	4.5	1.8	1.2
L-Phenylalanine	8.4	8.4	8.4
L-Threonine	7.2	7.2	7.2
L-Tryptophan	2.1	2.1	2.1
L-Valine	9.3	9.3	9.3
L-Histidine-HCl-H2O	4.6	4.6	4.6
L-Alanine	5.1	5.1	5.1
L-Arginine	6	6	6
L-Aspartic Acid	12.1	12.1	12.1
L-Glutamic Acid	38.2	38.2	38.2
Glycine	3	3	3
L-Proline	17.8	17.8	17.8
L-Serine	10	10	10
L-Tyrosine	9.2	9.2	9.2
Total L-Amino Acids	174.1	171.4	170.8
Corn Starch	506.2	506.2	506.2
Maltodextrin 10	125	125	125
Sucrose	73.6	76.3	76.9
Cellulose, BW200	50	50	50
Soybean Oil	25	25	25
Lard	20	20	20
Mineral Mix S10026	10	10	10
DiCalcium Phosphate	13	13	13
Calcium Carbonate	5.5	5.5	5.5
Potassium Citrate, 1 H2O	16.5	16.5	16.5
Sodium Bicarbonate	7.5	7.5	7.5
Vitamin Mix V10001	10	10	10
Choline Bitartrate	2	2	2
FD&C Blue Dye #1	0	0.05	0
FD&C Yellow Dye #5	0.05	0	0
FD&C Red Dye #40	0	0	0.05
Total	1038.450	1038.450	1038.450
gm			
Protein	174.1	171.4	170.8
Carbohydrate	714.8	717.5	718.1
Fat	45.0	45.0	45.0
Fiber	50.0	50.0	50.0
gm%			
Protein	16.8	16.5	16.4
Carbohydrate	68.8	69.1	69.2
Fat	4.3	4.3	4.3
Fiber	4.8	4.8	4.8
kcal			
Protein	696	686	683
Carbohydrate	2859	2870	2872
Fat	405	405	405
Total	3961	3961	3961
kcal%			
Protein	18	17	17
Carbohydrate	72	72	73
Fat	10	10	10
Total	100	100	100
kcal / gm	3.8	3.8	3.8

Research Diets, Inc.
20 Jules Lane
New Brunswick, NJ 08901 USA
info@researchdiets.com

A17101101-03.for



1315

1316

Supplemental Table 7 macronutrient composition of the control and SAAR diets used